[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$flaiOPDM-s3pPYiiyR8wsW0hfxgk6bTl53GkcDB5-apY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Otsuka Pharmaceutical Development & Commercialization, Inc.",[4],280,false,14,136,160064,21,10,[14,17,20,22,25,28,31,34],{"name":15,"count":16},"Schizophrenia",82,{"name":18,"count":19},"Major Depressive Disorder",15,{"name":21,"count":8},"Bipolar Disorder",{"name":23,"count":24},"Bipolar I Disorder",12,{"name":26,"count":27},"Depressive Disorder, Major",9,{"name":29,"count":30},"Mental Disorder",8,{"name":32,"count":33},"Healthy Volunteers",7,{"name":35,"count":33},"Major Depressive Disorder (MDD)",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT07455084","A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults","2026-04-10","14C-SEP-380135",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05248646","Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)","2026-05-07","Sibeprenlimab 400 mg",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT07446400","A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol\u002FNorethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together","2026-06-09","Repinatrabit",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06894212","A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia","2026-10-20","SEP-363856",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06799520","A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)","2026-12-01","VIS171",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07329621","A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults","2027-01-29","MSP-2020",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06928142","A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's","2027-03-13","Sibeprenlimab",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT07525960","A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the Body","2027-04-14","NDI-5001",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07209761","A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","2027-05-28","BPaQM",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06628128","A Long-Term Study of JNT-517 in Participants With Phenylketonuria","2027-11-01","JNT-517",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,151,384,561,588,613,631,649,667,685,707,739,768,798,831,849,867,885,903,924,944,965,1526,1798,1820,1844,1868,1886,1910,1928,1952,1970,1995,2013,2031,2049,2187,2298,2408,2447,2502,2553,2583,2613,2652,2682,2704,2732,2766,2800,2834,2869,2907,2929,2956,2980,2998,3016,3034,3056,3080,3098,3116,3134,3152,3170,3188,3206,3224,3242,3260,3283,3301,3319,3337,3355,3379,3397,3415,3438,3456,3474,3497,3515,3533,3558,3576,3600,3672,3713,3756,3791,3813,3847,3877,3899,3917,3935,3953,3971,3989,4007,4025,4043,4061,4079,4097,4115,4133,4157,4180,4204,4234,4252,4270,4288,4313,4331,4355,4378,4396,4422,4440,4464,4488,4506,4545,4567,4599,4621,4639,4657,4675,4693,4711,4729,4747,4765,4783,4807,4834,4852,4870,4888,4909,4932,4957,4975,4993,5011,5029,5047,5065,5091,5109,5133,5151,5178,5196,5214,5232,5254,5272,5290,5315,5333,5361,5379,5397,5415,5433,5456,5482,5507,5528,5553,5571,5596,5614,5632,5650,5668,5691,5714,5732,5753],{"intervention":86,"totalTrials":96,"cells":97},4,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":126,"PHASE4":147,"NA":149},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[105,115],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":8,"conditions":112,"interventions":114},"NCT06637514","A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria","COMPLETED",[90],"2026-05-08","2025-07-16",[113],"Phenylketonuria (PKU)",[86,86],{"nctId":116,"briefTitle":117,"status":108,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT05781399","First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria",[89,90],"2025-07-14","2022-10-31",111,[123],"Phenylketonuria",[125,86],"JNT-517 Suspension",{"trials":127,"activeCount":146,"soonestReadout":85},[128,136],{"nctId":83,"briefTitle":84,"status":129,"phases":130,"primaryCompletion":85,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":135},"RECRUITING",[91],"2028-02-01","2025-08-11",240,[113],[86],{"nctId":137,"briefTitle":138,"status":129,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":145},"NCT06971731","A Study of JNT-517 in Participants With Phenylketonuria (PKU)",[91],"2028-03-01","2028-04-01","2025-10-20",120,[123],[86,86],2,{"trials":148,"activeCount":100},[],{"trials":150,"activeCount":100},[],{"intervention":152,"totalTrials":153,"cells":154},"Tolvaptan",22,{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":221,"PHASE4":380,"NA":382},{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":100},[],{"trials":160,"activeCount":100},[161,172,182,192,202,211],{"nctId":162,"briefTitle":163,"status":108,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT00132886","Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure",[90],"2006-12","2004-12",140,[169],"Heart Failure, Congestive",[171],"tolvaptan",{"nctId":173,"briefTitle":174,"status":108,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":181},"NCT02009878","A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)",[89,90],"2015-06","2013-11",30,[180],"Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)",[171],{"nctId":183,"briefTitle":184,"status":108,"phases":185,"primaryCompletion":186,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},"NCT00413777","Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[90],"2010-06","2005-12",46,[190],"Polycystic Kidney, Autosomal Dominant",[152],{"nctId":193,"briefTitle":194,"status":108,"phases":195,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"NCT00043758","Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients",[90],"2004-07","2002-07",170,[200],"Congestive Heart Failure",[152],{"nctId":203,"briefTitle":204,"status":108,"phases":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":210},"NCT00043771","Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients",[90],"2002-09","2002-05",40,[200],[152],{"nctId":212,"briefTitle":213,"status":108,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT01336972","Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[90],"2011-11","2010-10",29,[219],"Autosomal Dominant Polycystic Kidney Disease",[152],{"trials":222,"activeCount":379,"soonestReadout":353},[223,233,244,255,264,276,286,295,304,314,322,332,340,349,361,370],{"nctId":224,"briefTitle":225,"status":108,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT02160145","Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease",[91],"2017-04-18","2014-05",1370,[231,219],"Chronic Kidney Disease",[152],{"nctId":234,"briefTitle":235,"status":236,"phases":237,"primaryCompletion":238,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":243},"NCT02020278","An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia","TERMINATED",[91],"2017-10-23","2016-04-22",3,[242],"Hyponatremia",[152],{"nctId":245,"briefTitle":246,"status":108,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT02964273","Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)",[91],"2021-11-17","2016-09-23",91,[252],"Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[152,254],"Tolvaptan Matching-placebo",{"nctId":256,"briefTitle":257,"status":108,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":263},"NCT00071331","EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan",[91],"2006-07","2003-09",3600,[200],[152],{"nctId":265,"briefTitle":266,"status":108,"phases":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":275},"NCT00201994","\"SALT-2 Trial\" Study of Ascending Levels of Tolvaptan in Hyponatremia",[91],"2005-07","2003-11",243,[242,272,273,274],"Water Intoxication","Inappropriate ADH Syndrome","Water-electrolyte Imbalance",[152],{"nctId":277,"briefTitle":278,"status":108,"phases":279,"completion":280,"start":281,"enrollment":133,"conditions":282,"interventions":285},"NCT00072683","\"SALT Trial\" Study of Ascending Levels of Tolvaptan in Hyponatremia",[91],"2006-02","2003-04",[283,272,273,284],"Hyponatremias","Water-Electrolyte Imbalances",[171],{"nctId":287,"briefTitle":288,"status":108,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":294},"NCT01214421","Tolvaptan Extension Study in Participants With ADPKD",[91],"2016-02-29","2010-05-26",1083,[252],[152],{"nctId":296,"briefTitle":297,"status":298,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":100,"conditions":302,"interventions":303},"NCT02442674","A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia","WITHDRAWN",[91],"2017-06-22","2015-11",[242],[152],{"nctId":305,"briefTitle":306,"status":108,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":313},"NCT00550459","Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients",[91],"2009-02","2009-03","2007-08",57,[242],[152],{"nctId":315,"briefTitle":316,"status":108,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":121,"conditions":320,"interventions":321},"NCT02449044","International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia",[91],"2009-10","2004-05",[242],[152],{"nctId":323,"briefTitle":324,"status":108,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":331},"NCT00428948","Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[91],"2012-01","2007-01",1445,[330],"Polycystic Kidney Disease, Autosomal Dominant",[152],{"nctId":333,"briefTitle":334,"status":236,"phases":335,"primaryCompletion":336,"completion":336,"start":337,"enrollment":27,"conditions":338,"interventions":339},"NCT02012959","Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia",[91],"2017-07-24","2015-09-22",[242],[152],{"nctId":341,"briefTitle":342,"status":236,"phases":343,"primaryCompletion":344,"completion":344,"start":216,"enrollment":345,"conditions":346,"interventions":348},"NCT01227512","Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia",[91],"2013-05",124,[242,347,273],"Dilutional Hyponatremia",[171],{"nctId":350,"briefTitle":351,"status":129,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":359},"NCT04782258","A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)",[91],"2028-07-31","2028-08-14","2023-01-23",20,[358],"Autosomal Recessive Polycystic Kidney (ARPKD)",[360,152],"Tolvaptan Suspension",{"nctId":362,"briefTitle":363,"status":298,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":100,"conditions":367,"interventions":369},"NCT04786574","A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)",[91],"2025-12-10","2022-07-01",[368],"Autosomal Recessive Polycystic Kidney Disease (ARPKD)",[152],{"nctId":371,"briefTitle":372,"status":108,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":378},"NCT02251275","Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease",[91],"2018-11-09","2014-10-17",1803,[190],[152],1,{"trials":381,"activeCount":100},[],{"trials":383,"activeCount":100},[],{"intervention":56,"totalTrials":385,"cells":386},18,{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":471,"PHASE3":511,"PHASE4":557,"NA":559},{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":100},[391,401,409,417,427,436,445,453,462],{"nctId":392,"briefTitle":393,"status":108,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":399},"NCT01972711","Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics",[89],"2015-07","2014-03",105,[15],[56,400],"Amisulpride",{"nctId":402,"briefTitle":403,"status":108,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":153,"conditions":407,"interventions":408},"NCT04038957","A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging",[89],"2023-06-06","2019-08-07",[15],[56],{"nctId":410,"briefTitle":411,"status":108,"phases":412,"primaryCompletion":413,"completion":413,"start":414,"enrollment":19,"conditions":415,"interventions":416},"NCT05463770","A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia",[89],"2023-08-22","2022-08-30",[15],[56],{"nctId":418,"briefTitle":419,"status":108,"phases":420,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":425},"NCT05542264","A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia",[89],"2024-02-12","2022-11-15",19,[15],[56,426],"Prior antipsychotic",{"nctId":428,"briefTitle":429,"status":108,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":435},"NCT05402111","A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard",[89],"2023-09-27","2022-06-13",31,[15],[56,426],{"nctId":437,"briefTitle":438,"status":108,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":11,"conditions":442,"interventions":443},"NCT04865835","A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.",[89],"2022-05-03","2021-05-12",[15],[56,444],"metformin",{"nctId":446,"briefTitle":447,"status":108,"phases":448,"primaryCompletion":396,"completion":396,"start":449,"enrollment":450,"conditions":451,"interventions":452},"NCT01940159","A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia",[89],"2013-08",48,[15],[56],{"nctId":454,"briefTitle":455,"status":108,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":461},"NCT05848700","A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia",[89],"2024-03-15","2023-06-21",60,[15],[56],{"nctId":463,"briefTitle":464,"status":108,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":450,"conditions":468,"interventions":469},"NCT01994473","Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia",[89],"2014-12","2013-10",[15],[56,470],"SEP-363856 Open Label",{"trials":472,"activeCount":100},[473,482,492,501],{"nctId":474,"briefTitle":475,"status":108,"phases":476,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":481},"NCT02970929","An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia",[90],"2019-01-29","2017-01-31",157,[15],[56],{"nctId":483,"briefTitle":484,"status":108,"phases":485,"primaryCompletion":486,"completion":486,"start":487,"enrollment":488,"conditions":489,"interventions":491},"NCT02969369","A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis",[90],"2020-04-20","2016-12-31",39,[490],"Parkinson Disease Psychosis",[56],{"nctId":493,"briefTitle":494,"status":108,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":500},"NCT02969382","A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia",[90],"2018-07-31","2016-12-05",245,[15],[56],{"nctId":502,"briefTitle":503,"status":108,"phases":504,"primaryCompletion":505,"completion":506,"start":507,"enrollment":508,"conditions":509,"interventions":510},"NCT05593029","A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder",[90],"2025-11-06","2025-11-13","2022-11-09",929,[18],[56],{"trials":512,"activeCount":379,"soonestReadout":55},[513,523,532,539,548],{"nctId":514,"briefTitle":515,"status":108,"phases":516,"primaryCompletion":517,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":522},"NCT05729373","A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder",[90,91],"2025-09-26","2023-03-08",434,[521],"Generalized Anxiety Disorder",[56],{"nctId":524,"briefTitle":525,"status":108,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":531},"NCT05628103","A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication",[91],"2024-04-01","2022-12-19",101,[15],[56],{"nctId":53,"briefTitle":54,"status":129,"phases":533,"primaryCompletion":55,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":538},[91],"2026-10-29","2025-02-28",522,[15],[56],{"nctId":540,"briefTitle":541,"status":108,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":547},"NCT05741528","An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication",[91],"2024-09-23","2023-03-31",75,[15],[56],{"nctId":549,"briefTitle":550,"status":236,"phases":551,"primaryCompletion":552,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":556},"NCT04109950","A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia",[91],"2023-11-09","2019-11-20",463,[15],[56],{"trials":558,"activeCount":100},[],{"trials":560,"activeCount":100},[],{"intervention":562,"totalTrials":379,"cells":563},"Sibeprenlimab 400 mg s.c. Q4weeks",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":584,"NA":586},{"trials":565,"activeCount":100},[],{"trials":567,"activeCount":100},[],{"trials":569,"activeCount":100},[],{"trials":571,"activeCount":379,"soonestReadout":577},[572],{"nctId":573,"briefTitle":574,"status":575,"phases":576,"primaryCompletion":577,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":583},"NCT05248659","Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)","ENROLLING_BY_INVITATION",[90,91],"2028-12-28","2029-12-31","2022-04-05",600,[582],"Immunoglobulin A Nephropathy",[562],{"trials":585,"activeCount":100},[],{"trials":587,"activeCount":100},[],{"intervention":81,"totalTrials":379,"cells":589},{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":596,"PHASE4":609,"NA":611},{"trials":591,"activeCount":100},[],{"trials":593,"activeCount":100},[],{"trials":595,"activeCount":100},[],{"trials":597,"activeCount":379,"soonestReadout":80},[598],{"nctId":78,"briefTitle":79,"status":129,"phases":599,"primaryCompletion":80,"completion":600,"start":601,"enrollment":602,"conditions":603,"interventions":605},[91],"2028-09-29","2025-10-16",532,[604],"Pulmonary Tuberculosis",[81,606,607,608],"BPaLM","BPaQ","BPaL",{"trials":610,"activeCount":100},[],{"trials":612,"activeCount":100},[],{"intervention":606,"totalTrials":379,"cells":614},{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":619,"PHASE3":621,"PHASE4":627,"NA":629},{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":100},[],{"trials":620,"activeCount":100},[],{"trials":622,"activeCount":379,"soonestReadout":80},[623],{"nctId":78,"briefTitle":79,"status":129,"phases":624,"primaryCompletion":80,"completion":600,"start":601,"enrollment":602,"conditions":625,"interventions":626},[91],[604],[81,606,607,608],{"trials":628,"activeCount":100},[],{"trials":630,"activeCount":100},[],{"intervention":607,"totalTrials":379,"cells":632},{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":645,"NA":647},{"trials":634,"activeCount":100},[],{"trials":636,"activeCount":100},[],{"trials":638,"activeCount":100},[],{"trials":640,"activeCount":379,"soonestReadout":80},[641],{"nctId":78,"briefTitle":79,"status":129,"phases":642,"primaryCompletion":80,"completion":600,"start":601,"enrollment":602,"conditions":643,"interventions":644},[91],[604],[81,606,607,608],{"trials":646,"activeCount":100},[],{"trials":648,"activeCount":100},[],{"intervention":608,"totalTrials":379,"cells":650},{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":663,"NA":665},{"trials":652,"activeCount":100},[],{"trials":654,"activeCount":100},[],{"trials":656,"activeCount":100},[],{"trials":658,"activeCount":379,"soonestReadout":80},[659],{"nctId":78,"briefTitle":79,"status":129,"phases":660,"primaryCompletion":80,"completion":600,"start":601,"enrollment":602,"conditions":661,"interventions":662},[91],[604],[81,606,607,608],{"trials":664,"activeCount":100},[],{"trials":666,"activeCount":100},[],{"intervention":360,"totalTrials":379,"cells":668},{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":681,"NA":683},{"trials":670,"activeCount":100},[],{"trials":672,"activeCount":100},[],{"trials":674,"activeCount":100},[],{"trials":676,"activeCount":379,"soonestReadout":353},[677],{"nctId":350,"briefTitle":351,"status":129,"phases":678,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":679,"interventions":680},[91],[358],[360,152],{"trials":682,"activeCount":100},[],{"trials":684,"activeCount":100},[],{"intervention":46,"totalTrials":379,"cells":686},{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":703,"NA":705},{"trials":688,"activeCount":100},[],{"trials":690,"activeCount":100},[],{"trials":692,"activeCount":100},[],{"trials":694,"activeCount":379,"soonestReadout":45},[695],{"nctId":43,"briefTitle":44,"status":696,"phases":697,"primaryCompletion":45,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":702},"ACTIVE_NOT_RECRUITING",[91],"2026-12-30","2022-03-15",530,[582],[46],{"trials":704,"activeCount":100},[],{"trials":706,"activeCount":100},[],{"intervention":71,"totalTrials":146,"cells":708},{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":733,"PHASE4":735,"NA":737},{"trials":710,"activeCount":100},[],{"trials":712,"activeCount":100},[],{"trials":714,"activeCount":146,"soonestReadout":70},[715,725],{"nctId":716,"briefTitle":717,"status":129,"phases":718,"primaryCompletion":719,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":724},"NCT06740526","Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue",[90],"2029-04-17","2024-11-19",25,[723],"IgA Nephropathy",[71],{"nctId":68,"briefTitle":69,"status":696,"phases":726,"primaryCompletion":70,"completion":727,"start":728,"enrollment":729,"conditions":730,"interventions":732},[90],"2027-06-04","2025-04-23",83,[731],"Sjogren Disease",[71],{"trials":734,"activeCount":100},[],{"trials":736,"activeCount":100},[],{"trials":738,"activeCount":100},[],{"intervention":740,"totalTrials":146,"cells":741},"Metformin",{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":766},{"trials":743,"activeCount":100},[],{"trials":745,"activeCount":379,"soonestReadout":50},[746,756],{"nctId":48,"briefTitle":49,"status":129,"phases":747,"primaryCompletion":50,"completion":748,"start":749,"enrollment":450,"conditions":750,"interventions":751},[89],"2026-06-15","2026-03-31",[32],[51,752,740,753,754,755],"EE\u002FNE","Rosuvastatin","Methotrexate","Carbamazepine",{"nctId":437,"briefTitle":438,"status":108,"phases":757,"primaryCompletion":440,"completion":440,"start":441,"enrollment":11,"conditions":758,"interventions":759},[89],[15],[56,444],{"trials":761,"activeCount":100},[],{"trials":763,"activeCount":100},[],{"trials":765,"activeCount":100},[],{"trials":767,"activeCount":100},[],{"intervention":755,"totalTrials":146,"cells":769},{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":796},{"trials":771,"activeCount":100},[],{"trials":773,"activeCount":379,"soonestReadout":50},[774,778],{"nctId":48,"briefTitle":49,"status":129,"phases":775,"primaryCompletion":50,"completion":748,"start":749,"enrollment":450,"conditions":776,"interventions":777},[89],[32],[51,752,740,753,754,755],{"nctId":779,"briefTitle":780,"status":108,"phases":781,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":787},"NCT07542847","A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women",[89],"2022-11-18","2022-12-11","2022-09-19",24,[32],[788,789,755],"OPC-167832","Itraconazole",{"trials":791,"activeCount":100},[],{"trials":793,"activeCount":100},[],{"trials":795,"activeCount":100},[],{"trials":797,"activeCount":100},[],{"intervention":61,"totalTrials":146,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":823,"PHASE3":825,"PHASE4":827,"NA":829},{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":379,"soonestReadout":60},[804,813],{"nctId":58,"briefTitle":59,"status":129,"phases":805,"primaryCompletion":60,"completion":806,"start":807,"enrollment":178,"conditions":808,"interventions":812},[89],"2027-03-01","2025-03-17",[809,810,811],"Systemic Lupus Erythematosus (SLE)","Alopecia Areata (AA)","Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)",[61],{"nctId":814,"briefTitle":815,"status":108,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":822},"NCT05418101","A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)",[89],"2024-03-13","2022-04-28",61,[821],"Autoimmune Diseases",[61],{"trials":824,"activeCount":100},[],{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":100},[],{"intervention":51,"totalTrials":379,"cells":832},{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":841,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":834,"activeCount":100},[],{"trials":836,"activeCount":379,"soonestReadout":50},[837],{"nctId":48,"briefTitle":49,"status":129,"phases":838,"primaryCompletion":50,"completion":748,"start":749,"enrollment":450,"conditions":839,"interventions":840},[89],[32],[51,752,740,753,754,755],{"trials":842,"activeCount":100},[],{"trials":844,"activeCount":100},[],{"trials":846,"activeCount":100},[],{"trials":848,"activeCount":100},[],{"intervention":752,"totalTrials":379,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":379,"soonestReadout":50},[855],{"nctId":48,"briefTitle":49,"status":129,"phases":856,"primaryCompletion":50,"completion":748,"start":749,"enrollment":450,"conditions":857,"interventions":858},[89],[32],[51,752,740,753,754,755],{"trials":860,"activeCount":100},[],{"trials":862,"activeCount":100},[],{"trials":864,"activeCount":100},[],{"trials":866,"activeCount":100},[],{"intervention":753,"totalTrials":379,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":877,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":379,"soonestReadout":50},[873],{"nctId":48,"briefTitle":49,"status":129,"phases":874,"primaryCompletion":50,"completion":748,"start":749,"enrollment":450,"conditions":875,"interventions":876},[89],[32],[51,752,740,753,754,755],{"trials":878,"activeCount":100},[],{"trials":880,"activeCount":100},[],{"trials":882,"activeCount":100},[],{"trials":884,"activeCount":100},[],{"intervention":754,"totalTrials":379,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":895,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":888,"activeCount":100},[],{"trials":890,"activeCount":379,"soonestReadout":50},[891],{"nctId":48,"briefTitle":49,"status":129,"phases":892,"primaryCompletion":50,"completion":748,"start":749,"enrollment":450,"conditions":893,"interventions":894},[89],[32],[51,752,740,753,754,755],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":100},[],{"trials":902,"activeCount":100},[],{"intervention":76,"totalTrials":379,"cells":904},{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":922},{"trials":906,"activeCount":100},[],{"trials":908,"activeCount":379,"soonestReadout":75},[909],{"nctId":73,"briefTitle":74,"status":910,"phases":911,"primaryCompletion":75,"completion":75,"start":912,"enrollment":785,"conditions":913,"interventions":915},"NOT_YET_RECRUITING",[89],"2026-06-02",[914],"X-linked Congenital Nephrogenic Diabetes Insipidus",[76],{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":100},[],{"trials":923,"activeCount":100},[],{"intervention":41,"totalTrials":379,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":936,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":927,"activeCount":100},[],{"trials":929,"activeCount":379,"soonestReadout":40},[930],{"nctId":38,"briefTitle":39,"status":910,"phases":931,"primaryCompletion":40,"completion":932,"start":933,"enrollment":30,"conditions":934,"interventions":935},[89],"2026-05-03","2026-03-20",[15],[41],{"trials":937,"activeCount":100},[],{"trials":939,"activeCount":100},[],{"trials":941,"activeCount":100},[],{"trials":943,"activeCount":100},[],{"intervention":66,"totalTrials":379,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":957,"PHASE3":959,"PHASE4":961,"NA":963},{"trials":947,"activeCount":100},[],{"trials":949,"activeCount":379,"soonestReadout":65},[950],{"nctId":63,"briefTitle":64,"status":129,"phases":951,"primaryCompletion":65,"completion":952,"start":953,"enrollment":385,"conditions":954,"interventions":956},[89],"2027-02-11","2026-01-15",[955],"Incomplete Response - Major Depressive Disorder (IR-MDD)",[66],{"trials":958,"activeCount":100},[],{"trials":960,"activeCount":100},[],{"trials":962,"activeCount":100},[],{"trials":964,"activeCount":100},[],{"intervention":966,"totalTrials":967,"cells":968},"Aripiprazole",62,{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":1011,"PHASE3":1048,"PHASE4":1450,"NA":1524},{"trials":970,"activeCount":100},[],{"trials":972,"activeCount":100},[973,984,994,1004],{"nctId":974,"briefTitle":975,"status":108,"phases":976,"primaryCompletion":977,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":981},"NCT01870999","A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot",[89],"2008-10","2007-11",41,[15],[982,983],"aripiprazole IM depot","aripiprazole",{"nctId":985,"briefTitle":986,"status":108,"phases":987,"primaryCompletion":988,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":993},"NCT03854409","A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder",[89],"2019-04-05","2020-02-20","2019-01-31",72,[15,23],[966],{"nctId":995,"briefTitle":996,"status":108,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1003},"NCT03150771","Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia",[89],"2018-04-18","2018-05-02","2017-06-14",36,[15],[966],{"nctId":1005,"briefTitle":1006,"status":108,"phases":1007,"primaryCompletion":1008,"completion":1008,"start":259,"enrollment":356,"conditions":1009,"interventions":1010},"NCT00321516","Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder",[89],"2007-02",[21],[983],{"trials":1012,"activeCount":100},[1013,1020,1029,1040],{"nctId":1014,"briefTitle":1015,"status":108,"phases":1016,"completion":268,"start":196,"conditions":1017,"interventions":1019},"NCT00102479","Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents",[90],[15,1018],"Mania",[966],{"nctId":1021,"briefTitle":1022,"status":108,"phases":1023,"primaryCompletion":1024,"completion":1024,"start":1025,"enrollment":1026,"conditions":1027,"interventions":1028},"NCT04030143","A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder",[89,90],"2020-07-08","2019-08-01",266,[15,23],[966,966],{"nctId":1030,"briefTitle":1031,"status":108,"phases":1032,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1038},"NCT00905307","Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia",[90],"2010-09","2010-11","2009-07",459,[15],[1039,966],"OPC-34712",{"nctId":1041,"briefTitle":1042,"status":298,"phases":1043,"primaryCompletion":228,"completion":466,"start":396,"enrollment":100,"conditions":1044,"interventions":1047},"NCT01981811","Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder",[90],[1045,15,29,1046],"Bipolar 1 Disorder","Nervous System Diseases",[966],{"trials":1049,"activeCount":100},[1050,1059,1070,1081,1091,1101,1109,1120,1131,1139,1148,1155,1163,1171,1179,1188,1196,1205,1217,1226,1238,1247,1255,1267,1275,1286,1292,1299,1306,1314,1322,1331,1337,1344,1352,1362,1371,1380,1386,1395,1404,1411,1418,1427,1435,1443],{"nctId":1051,"briefTitle":1052,"status":108,"phases":1053,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1058},"NCT00095511","Aripiprazole in Patients With Acute Mania",[91],"2007-05","2004-06",615,[21],[983],{"nctId":1060,"briefTitle":1061,"status":236,"phases":1062,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1067},"NCT01111539","Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole\u002FEscitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)",[91],"2011-09-20","2010-07-13",211,[35],[1068,966,1069],"Escitalopram","Blinded",{"nctId":1071,"briefTitle":1072,"status":108,"phases":1073,"primaryCompletion":1074,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1079},"NCT02054702","Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia",[91],"2014-06","2014-07","2014-02",97,[15],[1080,966],"Brexpiprazole",{"nctId":1082,"briefTitle":1083,"status":108,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1090},"NCT01418339","Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder",[91],"2013-11-06","2011-07-27",135,[1089],"Tourette's Disorder",[966],{"nctId":1092,"briefTitle":1093,"status":108,"phases":1094,"primaryCompletion":449,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1100},"NCT01727700","Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder",[91],"2013-09","2012-11",133,[1089,1099],"Tic Disorder",[966],{"nctId":1102,"briefTitle":1103,"status":108,"phases":1104,"primaryCompletion":1105,"completion":1105,"start":1106,"enrollment":198,"conditions":1107,"interventions":1108},"NCT01416441","Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder",[91],"2014-03-13","2011-10-19",[1089],[966],{"nctId":1110,"briefTitle":1111,"status":108,"phases":1112,"primaryCompletion":1113,"completion":1113,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1119},"NCT00095719","Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia",[91],"2005-03","2003-12",125,[1117,1118],"Dementia","Alzheimer's Disease",[966],{"nctId":1121,"briefTitle":1122,"status":108,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":1126,"conditions":1127,"interventions":1130},"NCT00337571","Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)",[91],"2008-06-01","2006-06-01",218,[1128,1129],"Behavioral Symptoms","Autistic Disorder",[966],{"nctId":1132,"briefTitle":1133,"status":108,"phases":1134,"primaryCompletion":1135,"completion":1135,"start":1125,"enrollment":1136,"conditions":1137,"interventions":1138},"NCT00332241","Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).",[91],"2008-04-01",98,[1129],[966],{"nctId":1140,"briefTitle":1141,"status":108,"phases":1142,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1147},"NCT00239356","Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials",[91],"2012-10","2003-03",119,[15],[966],{"nctId":1149,"briefTitle":1150,"status":108,"phases":1151,"primaryCompletion":1008,"completion":1008,"start":1113,"enrollment":1152,"conditions":1153,"interventions":1154},"NCT00110461","Aripiprazole in Children and Adolescents With Bipolar I Disorder",[91],296,[21],[966,966],{"nctId":1156,"briefTitle":1157,"status":108,"phases":1158,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":729,"conditions":1161,"interventions":1162},"NCT01418352","Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)",[91],"2014-03-12","2011-08-02",[1089],[966],{"nctId":1164,"briefTitle":1061,"status":236,"phases":1165,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":1168,"conditions":1169,"interventions":1170},"NCT01111552",[91],"2011-09-27","2010-07-29",237,[35],[1068,966],{"nctId":1172,"briefTitle":1173,"status":108,"phases":1174,"primaryCompletion":1144,"completion":1144,"start":1175,"conditions":1176,"interventions":1178},"NCT00041678","Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type",[91],"2000-01",[1177],"Alzheimer Disease",[983],{"nctId":1180,"briefTitle":1181,"status":108,"phases":1182,"primaryCompletion":1114,"completion":1114,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1186},"NCT00712686","Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia",[91],"2000-06",690,[15],[966,1187],"Olanzapine",{"nctId":1189,"briefTitle":1190,"status":108,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":206,"enrollment":1193,"conditions":1194,"interventions":1195},"NCT00237939","A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices",[91],"2006-11",1200,[15],[966],{"nctId":1197,"briefTitle":1198,"status":108,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1204},"NCT00257972","Study of Aripiprazole in Patients With Bipolar I Disorder",[91],"2007-12","2004-10",400,[21],[983],{"nctId":1206,"briefTitle":1207,"status":108,"phases":1208,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1216},"NCT00095524","Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder",[91],"2006-08","2004-03",300,[1213,15,1214,1215],"Body Weight Change","Schizoaffective Disorder","Psychotic Disorder",[966],{"nctId":1218,"briefTitle":1219,"status":108,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1225},"NCT00365859","Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)",[91],"2009-06","2006-09",330,[1129,1128],[966],{"nctId":1227,"briefTitle":1228,"status":108,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":1233,"interventions":1235},"NCT00665366","Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder",[91],"2011-10","2008-06",493,[1234],"Bipolar Disorder Mania",[966,1236,1237],"Lithium","Valproate",{"nctId":1239,"briefTitle":1240,"status":108,"phases":1241,"primaryCompletion":177,"completion":1242,"start":1243,"enrollment":1244,"conditions":1245,"interventions":1246},"NCT01149655","Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia",[91],"2013-12","2011-07",252,[15],[966,966],{"nctId":1248,"briefTitle":1249,"status":108,"phases":1250,"primaryCompletion":1251,"completion":1251,"start":197,"enrollment":1252,"conditions":1253,"interventions":1254},"NCT00036361","Broad Effectiveness: Study With Aripiprazole",[91],"2003-01",444,[15,1214],[966],{"nctId":1256,"briefTitle":1257,"status":236,"phases":1258,"primaryCompletion":1259,"completion":1260,"start":1261,"enrollment":1262,"conditions":1263,"interventions":1266},"NCT01122927","Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.",[91],"2014-08","2014-09","2010-07",524,[1264,1265],"Adolescent Schizophrenia","Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features",[966],{"nctId":1268,"briefTitle":1269,"status":108,"phases":1270,"primaryCompletion":1008,"completion":1008,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1274},"NCT00102518","Aripiprazole Open-Label, Safety and Tolerability Study",[91],"2004-09",325,[15,21],[966],{"nctId":1276,"briefTitle":1277,"status":236,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1284},"NCT00857818","Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome",[91],"2010-03","2009-04",64,[15,1214,23,1283],"Metabolic Syndrome",[966,1285],"Oanzapine, risperidone, or quetiapine",{"nctId":1287,"briefTitle":1288,"status":298,"phases":1289,"primaryCompletion":978,"completion":978,"start":165,"enrollment":100,"conditions":1290,"interventions":1291},"NCT00338273","A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode",[91],[21],[966],{"nctId":1293,"briefTitle":1294,"status":108,"phases":1295,"primaryCompletion":1251,"completion":1251,"start":1296,"conditions":1297,"interventions":1298},"NCT00036127","Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders",[90,91],"2002-04",[15],[983],{"nctId":1300,"briefTitle":1301,"status":108,"phases":1302,"primaryCompletion":978,"completion":978,"start":1113,"enrollment":1202,"conditions":1303,"interventions":1305},"NCT00292409","A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices",[91],[1304],"Schizophrenia and Schizoaffective Disorder",[966],{"nctId":1307,"briefTitle":1308,"status":108,"phases":1309,"primaryCompletion":1310,"completion":1310,"start":1311,"conditions":1312,"interventions":1313},"NCT00036348","Study of Aripiprazole in Patients With a History of Bipolar Disorder",[91],"2003-06","2000-03",[21],[966],{"nctId":1315,"briefTitle":1061,"status":236,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1321},"NCT01111565",[91],"2011-09-01","2010-10-04",137,[35],[1068,966],{"nctId":1323,"briefTitle":1324,"status":108,"phases":1325,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1330},"NCT01129882","An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia",[91],"2018-12-06","2010-06-24",709,[15],[966],{"nctId":1332,"briefTitle":1288,"status":108,"phases":1333,"primaryCompletion":1192,"completion":1192,"start":1055,"enrollment":1334,"conditions":1335,"interventions":1336},"NCT00094432",[91],650,[23],[966],{"nctId":1338,"briefTitle":1339,"status":108,"phases":1340,"primaryCompletion":327,"completion":327,"start":166,"enrollment":1056,"conditions":1341,"interventions":1342},"NCT00097266","Study of Aripiprazole in Patients With Acute Bipolar Mania",[91],[21],[966,1343],"Haloperidol",{"nctId":1345,"briefTitle":1346,"status":108,"phases":1347,"primaryCompletion":1259,"completion":1260,"start":1348,"enrollment":1349,"conditions":1350,"interventions":1351},"NCT01727713","Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder",[91],"2013-01",110,[1089,1099],[966],{"nctId":1353,"briefTitle":1354,"status":108,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":1096,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT01710709","Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder",[91],"2016-11","2016-12",748,[1360],"Bipolar I",[966],{"nctId":1363,"briefTitle":1364,"status":236,"phases":1365,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1370},"NCT02435836","A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia",[91],"2012-12","1998-04",631,[15],[966],{"nctId":1372,"briefTitle":1373,"status":108,"phases":1374,"primaryCompletion":1375,"completion":1375,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1379},"NCT01001702","Oral Aripiprazole Open-Label Rollover Study",[91],"2012-07","2006-04",85,[15],[966],{"nctId":1381,"briefTitle":1173,"status":108,"phases":1382,"primaryCompletion":1383,"completion":1383,"start":1311,"conditions":1384,"interventions":1385},"NCT00036114",[91],"2003-08",[1177],[983],{"nctId":1387,"briefTitle":1388,"status":108,"phases":1389,"primaryCompletion":1390,"completion":1390,"start":196,"enrollment":1391,"conditions":1392,"interventions":1393},"NCT00237913","Schizophrenia Trial of Aripiprazole",[91],"2005-08",700,[15],[966,1394],"Olanzapine or Quetiapine or Risperidone",{"nctId":1396,"briefTitle":1397,"status":108,"phases":1398,"primaryCompletion":1261,"completion":1261,"start":1399,"enrollment":1400,"conditions":1401,"interventions":1403},"NCT01438060","Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type",[91],"2000-08",232,[1402],"Dementia, Alzheimer Type",[966],{"nctId":1405,"briefTitle":1406,"status":108,"phases":1407,"primaryCompletion":1251,"completion":1251,"start":1408,"conditions":1409,"interventions":1410},"NCT00036101","Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder",[91],"2002-02",[21],[983],{"nctId":1412,"briefTitle":1413,"status":108,"phases":1414,"primaryCompletion":281,"completion":281,"start":1415,"conditions":1416,"interventions":1417},"NCT00046384","Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder",[91],"2002-06",[23],[983],{"nctId":1419,"briefTitle":1420,"status":108,"phases":1421,"primaryCompletion":1422,"completion":1422,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1426},"NCT03198078","Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia",[91],"2023-04-03","2017-06-30",316,[15],[1080,966],{"nctId":1428,"briefTitle":1429,"status":108,"phases":1430,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":1202,"conditions":1433,"interventions":1434},"NCT00080314","Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode",[91],"2006-10","2004-01",[21],[966],{"nctId":1436,"briefTitle":1437,"status":236,"phases":1438,"primaryCompletion":1166,"completion":1166,"start":1439,"enrollment":1440,"conditions":1441,"interventions":1442},"NCT01123707","To Assess the Safety and Tolerability of an Oral Aripiprazole\u002FEscitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)",[91],"2010-11-18",173,[35],[966,1068],{"nctId":1444,"briefTitle":1445,"status":108,"phases":1446,"primaryCompletion":1113,"completion":1113,"start":1210,"enrollment":1447,"conditions":1448,"interventions":1449},"NCT00101569","Aripiprazole Oral Acceptability Trial",[91],59,[15],[966,966],{"trials":1451,"activeCount":100},[1452,1462,1470,1478,1487,1500,1509,1517],{"nctId":1453,"briefTitle":1454,"status":108,"phases":1455,"primaryCompletion":1271,"completion":1271,"start":1456,"enrollment":1457,"conditions":1458,"interventions":1461},"NCT00095810","Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease",[92],"2003-07",50,[1459,1460],"Parkinson's Disease","Psychoses",[983],{"nctId":1463,"briefTitle":1464,"status":108,"phases":1465,"primaryCompletion":1466,"completion":1466,"start":187,"enrollment":1467,"conditions":1468,"interventions":1469},"NCT00300846","A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients",[92],"2007-07",200,[15],[983],{"nctId":1471,"briefTitle":1472,"status":108,"phases":1473,"primaryCompletion":1474,"completion":1474,"start":1113,"enrollment":1475,"conditions":1476,"interventions":1477},"NCT00329810","Effect on Cognitive Function of a Treatment With Aripiprazole",[92],"2006-03",500,[15],[966],{"nctId":1479,"briefTitle":1480,"status":236,"phases":1481,"primaryCompletion":1482,"completion":1482,"start":1483,"enrollment":1001,"conditions":1484,"interventions":1486},"NCT03661983","Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder",[92],"2020-06-30","2018-10-13",[1485],"Tourette's Disorder (TD)",[966],{"nctId":1488,"briefTitle":1489,"status":108,"phases":1490,"primaryCompletion":1491,"completion":1492,"start":1493,"enrollment":1494,"conditions":1495,"interventions":1497},"NCT03568500","A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic",[92],"2019-05-21","2019-09-06","2018-05-21",44,[15,1214,1496],"First Episode Psychosis",[966,1187,1498,1499],"Quetiapine","Risperidone",{"nctId":1501,"briefTitle":1502,"status":108,"phases":1503,"primaryCompletion":1504,"completion":1504,"start":1505,"enrollment":1506,"conditions":1507,"interventions":1508},"NCT00232687","A Switch Study of BMS-337039 in Schizophrenic Out-patients",[92],"2007-04","2005-06",450,[15],[966,966],{"nctId":1510,"briefTitle":1511,"status":108,"phases":1512,"primaryCompletion":1390,"completion":1390,"start":1513,"enrollment":1202,"conditions":1514,"interventions":1516},"NCT00082199","Study of Aripiprazole in Subjects With Alcoholism",[92],"2004-04",[1515],"Alcoholism",[966],{"nctId":1518,"briefTitle":1519,"status":108,"phases":1520,"primaryCompletion":1271,"completion":1271,"start":269,"enrollment":1521,"conditions":1522,"interventions":1523},"NCT00080327","Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia",[92],370,[15],[966,966,966],{"trials":1525,"activeCount":100},[],{"intervention":1080,"totalTrials":217,"cells":1527},{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1558,"PHASE3":1581,"PHASE4":1776,"NA":1796},{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[1532,1538,1549],{"nctId":1533,"briefTitle":1534,"status":108,"phases":1535,"primaryCompletion":344,"completion":344,"start":1375,"enrollment":385,"conditions":1536,"interventions":1537},"NCT01670279","Phase 1 Study to Assess the Safety\u002FTolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder",[89],[18],[1080],{"nctId":1539,"briefTitle":1540,"status":108,"phases":1541,"primaryCompletion":1493,"completion":1493,"start":1542,"enrollment":785,"conditions":1543,"interventions":1548},"NCT03292848","Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to \u003C13 Years Old) With Central Nervous System Disorders",[89],"2017-10-10",[1544,1545,23,1546,1547],"ADHD","Autism","Conduct Disorder","Oppositional Defiant Disorder",[1080],{"nctId":1550,"briefTitle":1551,"status":108,"phases":1552,"primaryCompletion":1553,"completion":1553,"start":1554,"enrollment":1555,"conditions":1556,"interventions":1557},"NCT02411695","Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia",[89],"2017-01-01","2015-03",43,[15],[1080],{"trials":1559,"activeCount":100},[1560,1570],{"nctId":1561,"briefTitle":1562,"status":108,"phases":1563,"primaryCompletion":1564,"completion":1564,"start":1565,"enrollment":1566,"conditions":1567,"interventions":1569},"NCT04100096","A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder",[90],"2021-06-27","2019-10-17",332,[1568],"Borderline Personality Disorder",[1080],{"nctId":1571,"briefTitle":1572,"status":108,"phases":1573,"primaryCompletion":1574,"completion":1574,"start":1575,"enrollment":1576,"conditions":1577,"interventions":1579},"NCT03033069","A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)",[90],"2018-11-12","2017-01-26",336,[1578],"Stress Disorders, Post-Traumatic",[1080,1580],"Sertraline",{"trials":1582,"activeCount":100},[1583,1591,1595,1606,1615,1625,1634,1642,1652,1661,1675,1686,1695,1702,1711,1719,1727,1739,1743,1750,1757,1767],{"nctId":1584,"briefTitle":1585,"status":108,"phases":1586,"primaryCompletion":228,"completion":1074,"start":177,"enrollment":1587,"conditions":1588,"interventions":1590},"NCT02013531","Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms",[91],37,[18,1589],"Anxiety",[1080],{"nctId":1071,"briefTitle":1072,"status":108,"phases":1592,"primaryCompletion":1074,"completion":1075,"start":1076,"enrollment":1077,"conditions":1593,"interventions":1594},[91],[15],[1080,966],{"nctId":1596,"briefTitle":1597,"status":108,"phases":1598,"primaryCompletion":1599,"completion":1600,"start":1601,"enrollment":1602,"conditions":1603,"interventions":1604},"NCT03538691","A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder",[91],"2022-07-08","2022-07-29","2018-07-13",1149,[18],[1080,1605],"Antidepressant therapy",{"nctId":1607,"briefTitle":1608,"status":108,"phases":1609,"primaryCompletion":1610,"completion":1611,"start":1143,"enrollment":1262,"conditions":1612,"interventions":1614},"NCT01668797","Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",[91],"2015-01","2015-02",[1613],"Acute Schizophrenia",[1080],{"nctId":1616,"briefTitle":1617,"status":108,"phases":1618,"primaryCompletion":1619,"completion":1619,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1624},"NCT03257865","A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder",[91],"2019-01-22","2017-09-19",333,[23,1623],"Manic Episode",[1080],{"nctId":1626,"briefTitle":1627,"status":108,"phases":1628,"primaryCompletion":1629,"completion":1629,"start":1630,"enrollment":1631,"conditions":1632,"interventions":1633},"NCT04186403","Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)",[90,91],"2021-09-22","2020-01-13",201,[1568],[1080],{"nctId":1635,"briefTitle":1636,"status":108,"phases":1637,"primaryCompletion":784,"completion":784,"start":1638,"enrollment":1639,"conditions":1640,"interventions":1641},"NCT03594123","A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",[91],"2018-10-11",259,[1118],[1080,1080],{"nctId":1643,"briefTitle":1644,"status":108,"phases":1645,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":1648,"conditions":1649,"interventions":1651},"NCT03287869","A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.",[91],"2019-07-31","2017-10-24",381,[23,1650],"Acute Mania",[1080],{"nctId":1653,"briefTitle":1654,"status":108,"phases":1655,"primaryCompletion":1656,"completion":1656,"start":1657,"enrollment":1658,"conditions":1659,"interventions":1660},"NCT03238326","Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia",[91],"2025-04-22","2017-08-23",295,[15],[1080],{"nctId":1662,"briefTitle":1663,"status":108,"phases":1664,"primaryCompletion":1665,"completion":1666,"start":1366,"enrollment":1667,"conditions":1668,"interventions":1673},"NCT01727726","A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial",[91],"2016-10-17","2016-11-10",2182,[1669,1670,26,1671,1672],"Depressive Disorder","Depression","Mood Disorders","Mental Disorders",[1080,1674],"Seroquel XR",{"nctId":1676,"briefTitle":1677,"status":108,"phases":1678,"primaryCompletion":1679,"completion":1680,"start":1681,"enrollment":1682,"conditions":1683,"interventions":1685},"NCT04174170","Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder",[91],"2023-07-25","2023-08-15","2019-10-30",591,[1684],"Post Traumatic Stress Disorder",[1080,1580,1080],{"nctId":1687,"briefTitle":1688,"status":108,"phases":1689,"primaryCompletion":1690,"completion":1691,"start":1681,"enrollment":1145,"conditions":1692,"interventions":1694},"NCT04174365","Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder",[91],"2022-08-08","2022-09-09",[1693],"Irritability Associated With Autism Spectrum Disorder (ASD)",[1080],{"nctId":1696,"briefTitle":1697,"status":298,"phases":1698,"primaryCompletion":301,"completion":301,"start":1260,"enrollment":100,"conditions":1699,"interventions":1701},"NCT02212613","Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability",[91],[1700],"Major Depressive Disorder and Irritability",[1080],{"nctId":1703,"briefTitle":1704,"status":108,"phases":1705,"primaryCompletion":1706,"completion":1706,"start":1707,"enrollment":1708,"conditions":1709,"interventions":1710},"NCT03259555","A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder",[91],"2019-01-02","2017-09-14",322,[23,1623],[1080],{"nctId":1712,"briefTitle":1713,"status":108,"phases":1714,"primaryCompletion":1715,"completion":1716,"start":1565,"enrollment":1506,"conditions":1717,"interventions":1718},"NCT04124614","Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD",[91],"2023-07-19","2023-08-08",[1684],[1080,1580],{"nctId":1720,"briefTitle":1721,"status":108,"phases":1722,"primaryCompletion":1260,"completion":1723,"start":177,"enrollment":450,"conditions":1724,"interventions":1726},"NCT02013609","Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment",[91],"2014-10",[1725],"MDD",[1080],{"nctId":1728,"briefTitle":1729,"status":108,"phases":1730,"primaryCompletion":1731,"completion":1732,"start":1733,"enrollment":1734,"conditions":1735,"interventions":1738},"NCT03548584","A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type",[91],"2022-05-23","2022-06-01","2018-05-16",345,[1736,1737],"Agitation Associated With Alzheimer's Dementia","Alzheimer Dementia",[1080],{"nctId":1419,"briefTitle":1420,"status":108,"phases":1740,"primaryCompletion":1422,"completion":1422,"start":1423,"enrollment":1424,"conditions":1741,"interventions":1742},[91],[15],[1080,966],{"nctId":1744,"briefTitle":1745,"status":108,"phases":1746,"primaryCompletion":1723,"completion":1723,"start":177,"enrollment":819,"conditions":1747,"interventions":1748},"NCT02012218","Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy",[91],[35],[1749,1080],"ADT",{"nctId":1751,"briefTitle":1752,"status":108,"phases":1753,"primaryCompletion":1260,"completion":1723,"start":177,"enrollment":1754,"conditions":1755,"interventions":1756},"NCT02013622","Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia",[91],49,[15],[1080],{"nctId":1758,"briefTitle":1759,"status":108,"phases":1760,"primaryCompletion":1761,"completion":1761,"start":1762,"enrollment":1763,"conditions":1764,"interventions":1766},"NCT04258839","Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148",[91],"2023-03-16","2020-01-23",95,[1765],"Irritability Associated With Autism Spectrum Disorder",[1080],{"nctId":1768,"briefTitle":1769,"status":108,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":1611,"enrollment":1772,"conditions":1773,"interventions":1775},"NCT02194933","Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity",[91],"2016-04",38,[1774],"Schizophrenia With Impulsivity",[1080],{"trials":1777,"activeCount":100},[1778,1787],{"nctId":1779,"briefTitle":1780,"status":108,"phases":1781,"primaryCompletion":1782,"completion":1782,"start":1783,"enrollment":1784,"conditions":1785,"interventions":1786},"NCT04830215","Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder",[92],"2022-05-27","2021-04-01",122,[18],[1080],{"nctId":1788,"briefTitle":1789,"status":298,"phases":1790,"primaryCompletion":1791,"completion":1792,"start":1793,"enrollment":100,"conditions":1794,"interventions":1795},"NCT05504486","Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety",[92],"2023-03-22","2023-04-05","2022-08-29",[35],[1080],{"trials":1797,"activeCount":100},[],{"intervention":1187,"totalTrials":146,"cells":1799},{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1806,"PHASE4":1812,"NA":1818},{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[],{"trials":1805,"activeCount":100},[],{"trials":1807,"activeCount":100},[1808],{"nctId":1180,"briefTitle":1181,"status":108,"phases":1809,"primaryCompletion":1114,"completion":1114,"start":1183,"enrollment":1184,"conditions":1810,"interventions":1811},[91],[15],[966,1187],{"trials":1813,"activeCount":100},[1814],{"nctId":1488,"briefTitle":1489,"status":108,"phases":1815,"primaryCompletion":1491,"completion":1492,"start":1493,"enrollment":1494,"conditions":1816,"interventions":1817},[92],[15,1214,1496],[966,1187,1498,1499],{"trials":1819,"activeCount":100},[],{"intervention":1821,"totalTrials":379,"cells":1822},"Combination product of Aripiprazole + IEM + Sensor + MIND1 Application",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1831,"NA":1842},{"trials":1824,"activeCount":100},[],{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[1833],{"nctId":1834,"briefTitle":1835,"status":108,"phases":1836,"primaryCompletion":1837,"completion":1837,"start":1838,"enrollment":178,"conditions":1839,"interventions":1841},"NCT02091882","Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)",[92],"2014-04-18","2014-03-21",[1840],"Device Latency",[1821],{"trials":1843,"activeCount":100},[],{"intervention":1845,"totalTrials":379,"cells":1846},"Quetiapine or Risperidone + Aripiprazole",{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1853,"PHASE4":1855,"NA":1866},{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":100},[],{"trials":1856,"activeCount":100},[1857],{"nctId":1858,"briefTitle":1859,"status":108,"phases":1860,"primaryCompletion":1861,"completion":1861,"start":259,"enrollment":1862,"conditions":1863,"interventions":1864},"NCT00325689","Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.",[92],"2007-10",323,[15,1214],[1845,1865],"Quetiapine or Risperidone + placebo",{"trials":1867,"activeCount":100},[],{"intervention":1865,"totalTrials":379,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1874,"PHASE3":1876,"PHASE4":1878,"NA":1884},{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"trials":1875,"activeCount":100},[],{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":100},[1880],{"nctId":1858,"briefTitle":1859,"status":108,"phases":1881,"primaryCompletion":1861,"completion":1861,"start":259,"enrollment":1862,"conditions":1882,"interventions":1883},[92],[15,1214],[1845,1865],{"trials":1885,"activeCount":100},[],{"intervention":1887,"totalTrials":379,"cells":1888},"Abilify MyCite - Digital Medicine System",{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1897,"NA":1908},{"trials":1890,"activeCount":100},[],{"trials":1892,"activeCount":100},[],{"trials":1894,"activeCount":100},[],{"trials":1896,"activeCount":100},[],{"trials":1898,"activeCount":100},[1899],{"nctId":1900,"briefTitle":1901,"status":236,"phases":1902,"primaryCompletion":1903,"completion":1903,"start":1904,"enrollment":146,"conditions":1905,"interventions":1906},"NCT03643159","A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder",[92],"2018-10-17","2018-06-28",[15,1045,18],[1887,1907],"Aripiprazole or other oral antipsychotics",{"trials":1909,"activeCount":100},[],{"intervention":1907,"totalTrials":379,"cells":1911},{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1916,"PHASE3":1918,"PHASE4":1920,"NA":1926},{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[],{"trials":1917,"activeCount":100},[],{"trials":1919,"activeCount":100},[],{"trials":1921,"activeCount":100},[1922],{"nctId":1900,"briefTitle":1901,"status":236,"phases":1923,"primaryCompletion":1903,"completion":1903,"start":1904,"enrollment":146,"conditions":1924,"interventions":1925},[92],[15,1045,18],[1887,1907],{"trials":1927,"activeCount":100},[],{"intervention":1929,"totalTrials":379,"cells":1930},"Lithium or Valproate with placebo",{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1937,"PHASE4":1939,"NA":1950},{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[1941],{"nctId":1942,"briefTitle":1943,"status":108,"phases":1944,"primaryCompletion":1221,"completion":318,"start":1945,"enrollment":1946,"conditions":1947,"interventions":1948},"NCT00261443","A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania",[92],"2005-09",1270,[21],[1929,1949],"Lithium or Valproate with Aripiprazole",{"trials":1951,"activeCount":100},[],{"intervention":1949,"totalTrials":379,"cells":1953},{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1960,"PHASE4":1962,"NA":1968},{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":100},[1964],{"nctId":1942,"briefTitle":1943,"status":108,"phases":1965,"primaryCompletion":1221,"completion":318,"start":1945,"enrollment":1946,"conditions":1966,"interventions":1967},[92],[21],[1929,1949],{"trials":1969,"activeCount":100},[],{"intervention":1971,"totalTrials":379,"cells":1972},"Lamotrigine + Aripiprazole",{"EARLY_PHASE1":1973,"PHASE1":1975,"PHASE2":1977,"PHASE3":1979,"PHASE4":1981,"NA":1993},{"trials":1974,"activeCount":100},[],{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":100},[],{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":100},[1983],{"nctId":1984,"briefTitle":1985,"status":108,"phases":1986,"primaryCompletion":1987,"completion":1987,"start":1988,"enrollment":1989,"conditions":1990,"interventions":1991},"NCT00277212","A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode",[92],"2009-07-01","2005-12-01",1169,[21],[1971,1992],"Lamotrigine + Placebo",{"trials":1994,"activeCount":100},[],{"intervention":1992,"totalTrials":379,"cells":1996},{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2003,"PHASE4":2005,"NA":2011},{"trials":1998,"activeCount":100},[],{"trials":2000,"activeCount":100},[],{"trials":2002,"activeCount":100},[],{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[2007],{"nctId":1984,"briefTitle":1985,"status":108,"phases":2008,"primaryCompletion":1987,"completion":1987,"start":1988,"enrollment":1989,"conditions":2009,"interventions":2010},[92],[21],[1971,1992],{"trials":2012,"activeCount":100},[],{"intervention":1498,"totalTrials":379,"cells":2014},{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2021,"PHASE4":2023,"NA":2029},{"trials":2016,"activeCount":100},[],{"trials":2018,"activeCount":100},[],{"trials":2020,"activeCount":100},[],{"trials":2022,"activeCount":100},[],{"trials":2024,"activeCount":100},[2025],{"nctId":1488,"briefTitle":1489,"status":108,"phases":2026,"primaryCompletion":1491,"completion":1492,"start":1493,"enrollment":1494,"conditions":2027,"interventions":2028},[92],[15,1214,1496],[966,1187,1498,1499],{"trials":2030,"activeCount":100},[],{"intervention":1499,"totalTrials":379,"cells":2032},{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2047},{"trials":2034,"activeCount":100},[],{"trials":2036,"activeCount":100},[],{"trials":2038,"activeCount":100},[],{"trials":2040,"activeCount":100},[],{"trials":2042,"activeCount":100},[2043],{"nctId":1488,"briefTitle":1489,"status":108,"phases":2044,"primaryCompletion":1491,"completion":1492,"start":1493,"enrollment":1494,"conditions":2045,"interventions":2046},[92],[15,1214,1496],[966,1187,1498,1499],{"trials":2048,"activeCount":100},[],{"intervention":2050,"totalTrials":2051,"cells":2052},"AVP-786",13,{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2096,"PHASE3":2125,"PHASE4":2183,"NA":2185},{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[2057,2069,2079,2087],{"nctId":2058,"briefTitle":2059,"status":108,"phases":2060,"primaryCompletion":396,"completion":2061,"start":2062,"enrollment":2063,"conditions":2064,"interventions":2066},"NCT02174822","A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects",[89],"2014-04","2014-01",56,[2065],"Drug-drug Interaction",[2050,2067,2068],"Paroxetine","Duloxetine",{"nctId":2070,"briefTitle":2071,"status":108,"phases":2072,"primaryCompletion":2073,"completion":2073,"start":2074,"enrollment":2063,"conditions":2075,"interventions":2077},"NCT02174835","A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers",[89],"2013-11-01","2013-09-01",[2076],"Healthy",[2050,2078],"AVP-923",{"nctId":2080,"briefTitle":2081,"status":108,"phases":2082,"primaryCompletion":2083,"completion":2083,"start":2084,"enrollment":785,"conditions":2085,"interventions":2086},"NCT02402595","Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts",[89],"2015-07-01","2015-03-01",[2076],[2078,2050,789],{"nctId":2088,"briefTitle":2089,"status":108,"phases":2090,"primaryCompletion":2091,"completion":2084,"start":2092,"enrollment":967,"conditions":2093,"interventions":2095},"NCT02336347","A Phase 1 Study Comparing AVP-786 With AVP-923",[89],"2014-09-01","2014-05-01",[2094],"Healthy Volunteer",[2050,2078],{"trials":2097,"activeCount":100},[2098,2107,2116],{"nctId":2099,"briefTitle":2100,"status":236,"phases":2101,"primaryCompletion":2102,"completion":2102,"start":2103,"enrollment":379,"conditions":2104,"interventions":2106},"NCT02534038","Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition",[90],"2017-10-03","2015-12-01",[2105],"Disinhibition Syndrome",[2050],{"nctId":2108,"briefTitle":2109,"status":108,"phases":2110,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":2113,"conditions":2114,"interventions":2115},"NCT02477670","Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia",[90],"2017-07-21","2015-09-01",145,[15],[2050],{"nctId":2117,"briefTitle":2118,"status":236,"phases":2119,"primaryCompletion":2120,"completion":2120,"start":2121,"enrollment":12,"conditions":2122,"interventions":2124},"NCT03420222","Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder",[90],"2018-12-28","2018-01-18",[2123],"Intermittent Explosive Disorder",[2050],{"trials":2126,"activeCount":100},[2127,2138,2147,2156,2166,2174],{"nctId":2128,"briefTitle":2129,"status":108,"phases":2130,"primaryCompletion":2131,"completion":2132,"start":2133,"enrollment":2134,"conditions":2135,"interventions":2137},"NCT03393520","Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]\u002FQuinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",[91],"2023-11-17","2023-12-14","2017-10-13",601,[2136],"Agitation in Patients With Dementia of the Alzheimer's Type",[2050],{"nctId":2139,"briefTitle":2140,"status":236,"phases":2141,"primaryCompletion":2142,"completion":2142,"start":2143,"enrollment":2144,"conditions":2145,"interventions":2146},"NCT04464564","Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",[91],"2024-06-28","2020-09-11",241,[2136],[2050],{"nctId":2148,"briefTitle":2149,"status":236,"phases":2150,"primaryCompletion":2151,"completion":2151,"start":2152,"enrollment":2153,"conditions":2154,"interventions":2155},"NCT04408755","Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",[91],"2024-06-27","2020-07-13",184,[2136],[2050],{"nctId":2157,"briefTitle":2158,"status":108,"phases":2159,"primaryCompletion":2160,"completion":2161,"start":2162,"enrollment":2163,"conditions":2164,"interventions":2165},"NCT02442765","Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",[91],"2019-01-30","2019-02-27","2015-07-23",387,[2136],[2050],{"nctId":2167,"briefTitle":2168,"status":236,"phases":2169,"primaryCompletion":2170,"completion":2170,"start":2171,"enrollment":9,"conditions":2172,"interventions":2173},"NCT03896945","Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia",[90,91],"2023-05-23","2019-02-15",[15],[2050],{"nctId":2175,"briefTitle":2176,"status":236,"phases":2177,"primaryCompletion":2178,"completion":2178,"start":2179,"enrollment":2180,"conditions":2181,"interventions":2182},"NCT02446132","Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",[91],"2024-09-06","2015-11-13",1197,[2136],[2050],{"trials":2184,"activeCount":100},[],{"trials":2186,"activeCount":100},[],{"intervention":1039,"totalTrials":24,"cells":2188},{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2227,"PHASE3":2266,"PHASE4":2294,"NA":2296},{"trials":2190,"activeCount":100},[],{"trials":2192,"activeCount":100},[2193,2202,2209,2218],{"nctId":2194,"briefTitle":2195,"status":108,"phases":2196,"primaryCompletion":2197,"completion":1243,"start":2198,"enrollment":2199,"conditions":2200,"interventions":2201},"NCT01299454","A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects",[89],"2011-06","2010-12",45,[15],[1039],{"nctId":2203,"briefTitle":2204,"status":108,"phases":2205,"primaryCompletion":1035,"completion":1035,"start":2206,"enrollment":19,"conditions":2207,"interventions":2208},"NCT00805454","Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712",[89],"2008-12",[15],[1039],{"nctId":2210,"briefTitle":2211,"status":108,"phases":2212,"primaryCompletion":2213,"completion":2214,"start":1243,"enrollment":1126,"conditions":2215,"interventions":2216},"NCT01423916","Trial to Evaluate the Effects of OPC-34712 on QT\u002FQTc in Subjects With Schizophrenia or Schizoaffective Disorder",[89],"2012-02","2012-03",[15,1214],[1039,2217,1039],"Moxifloxacin",{"nctId":2219,"briefTitle":2220,"status":108,"phases":2221,"primaryCompletion":2222,"completion":326,"start":2223,"enrollment":423,"conditions":2224,"interventions":2226},"NCT01289080","Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects",[89],"2011-12","2011-01",[15,2225],"Psychiatric Disorders",[1039],{"trials":2228,"activeCount":100},[2229,2237,2241,2249,2259],{"nctId":2230,"briefTitle":2231,"status":108,"phases":2232,"primaryCompletion":186,"completion":1261,"start":2233,"enrollment":2234,"conditions":2235,"interventions":2236},"NCT00797966","Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder",[90],"2009-05",850,[18],[1039,1749],{"nctId":1030,"briefTitle":1031,"status":108,"phases":2238,"primaryCompletion":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":2239,"interventions":2240},[90],[15],[1039,966],{"nctId":2242,"briefTitle":2243,"status":108,"phases":2244,"primaryCompletion":1366,"completion":1366,"start":2245,"enrollment":2246,"conditions":2247,"interventions":2248},"NCT01447576","Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder",[90],"2009-09",1036,[18],[1749,1039],{"nctId":2250,"briefTitle":2251,"status":108,"phases":2252,"primaryCompletion":2253,"completion":2254,"start":2255,"enrollment":2256,"conditions":2257,"interventions":2258},"NCT01649557","Multicenter, Open-label, Safety and Tolerability Study",[90],"2011-08","2011-09","2009-08",244,[15],[1039],{"nctId":2260,"briefTitle":2261,"status":108,"phases":2262,"primaryCompletion":1230,"completion":215,"start":1279,"enrollment":2263,"conditions":2264,"interventions":2265},"NCT01052077","Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder",[90],773,[18],[1039,1749],{"trials":2267,"activeCount":100},[2268,2275,2286],{"nctId":2269,"briefTitle":2270,"status":108,"phases":2271,"primaryCompletion":1076,"completion":1076,"start":1243,"enrollment":2272,"conditions":2273,"interventions":2274},"NCT01393613","Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia",[91],674,[1613],[1039,1039,1039],{"nctId":2276,"briefTitle":2277,"status":108,"phases":2278,"primaryCompletion":227,"completion":2279,"start":1230,"enrollment":2280,"conditions":2281,"interventions":2282},"NCT01360866","Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)",[91],"2017-05-18",2944,[1669,1670,26,1671,1672],[1039,1068,2283,2284,1580,2068,2285],"Fluoxetine","Paroxetine CR","Venlafaxine XR",{"nctId":2287,"briefTitle":2288,"status":108,"phases":2289,"primaryCompletion":2290,"completion":2290,"start":2254,"enrollment":2291,"conditions":2292,"interventions":2293},"NCT01397786","Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia",[91],"2016-01",1044,[15],[1039],{"trials":2295,"activeCount":100},[],{"trials":2297,"activeCount":100},[],{"intervention":2299,"totalTrials":12,"cells":2300},"Centanafadine",{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2342,"PHASE3":2380,"PHASE4":2404,"NA":2406},{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[2305,2313,2324,2333],{"nctId":2306,"briefTitle":2307,"status":108,"phases":2308,"primaryCompletion":2309,"completion":2309,"start":518,"enrollment":1494,"conditions":2310,"interventions":2312},"NCT07486895","Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects",[89],"2023-05-18",[2311],"Healthy Adult Participants",[2299],{"nctId":2314,"briefTitle":2315,"status":108,"phases":2316,"primaryCompletion":2317,"completion":2318,"start":2319,"enrollment":208,"conditions":2320,"interventions":2321},"NCT07314333","A Trial to Assess How Centanafadine Interacts With Stimulants in the Body",[89],"2026-03-30","2026-04-15","2026-02-05",[1544],[2299,2322,2323],"Methylphenidate","Lisdexamfetamine",{"nctId":2325,"briefTitle":2326,"status":108,"phases":2327,"primaryCompletion":2328,"completion":2328,"start":2329,"enrollment":1457,"conditions":2330,"interventions":2332},"NCT04786730","A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder",[89],"2023-04-26","2021-03-09",[2331],"Attention-deficit Hyperactivity Disorder",[2299],{"nctId":2334,"briefTitle":2335,"status":108,"phases":2336,"primaryCompletion":1783,"completion":1783,"start":2337,"enrollment":2338,"conditions":2339,"interventions":2341},"NCT04398225","A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit\u002FHyperactivity Disorder",[89],"2020-06-11",32,[2340],"Attention Deficit Hyperactivity Disorder",[2299],{"trials":2343,"activeCount":100},[2344,2352,2361,2370],{"nctId":2345,"briefTitle":2346,"status":108,"phases":2347,"primaryCompletion":2348,"completion":2348,"start":2349,"enrollment":2051,"conditions":2350,"interventions":2351},"NCT04081363","Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)",[90],"2019-12-21","2019-10-07",[2340],[2299],{"nctId":2353,"briefTitle":2354,"status":108,"phases":2355,"primaryCompletion":2356,"completion":2356,"start":2357,"enrollment":1457,"conditions":2358,"interventions":2360},"NCT05066724","Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment",[90],"2022-05-31","2021-09-15",[2359],"Smoking Cessation",[2299],{"nctId":2362,"briefTitle":2363,"status":108,"phases":2364,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":2367,"conditions":2368,"interventions":2369},"NCT05536414","Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder",[90],"2025-05-16","2022-09-12",337,[18],[2299,1068],{"nctId":2371,"briefTitle":2372,"status":108,"phases":2373,"primaryCompletion":2374,"completion":2374,"start":2375,"enrollment":2376,"conditions":2377,"interventions":2379},"NCT05113953","A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder",[90],"2022-08-19","2021-12-22",147,[2378],"Binge-Eating Disorder",[2299],{"trials":2381,"activeCount":100},[2382,2392],{"nctId":2383,"briefTitle":2384,"status":108,"phases":2385,"primaryCompletion":807,"completion":807,"start":2386,"enrollment":2387,"conditions":2388,"interventions":2390},"NCT05428033","A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit\u002F Hyperactivity Disorder (ADHD)",[91],"2022-07-11",574,[2389],"Attention Deficit\u002FHyperactivity Disorder",[2391],"centanafadine",{"nctId":2393,"briefTitle":2394,"status":108,"phases":2395,"primaryCompletion":2396,"completion":2397,"start":2398,"enrollment":2399,"conditions":2400,"interventions":2403},"NCT06973577","P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety",[91],"2026-04-22","2026-04-29","2025-03-26",315,[1544,1589,2401,2402],"Generalized Anxiety","Social Anxiety Disorder",[2299],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"intervention":1068,"totalTrials":2409,"cells":2410},6,{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2421,"PHASE4":2443,"NA":2445},{"trials":2412,"activeCount":100},[],{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":100},[2417],{"nctId":2362,"briefTitle":2363,"status":108,"phases":2418,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":2367,"conditions":2419,"interventions":2420},[90],[18],[2299,1068],{"trials":2422,"activeCount":100},[2423,2427,2431,2435,2439],{"nctId":1060,"briefTitle":1061,"status":236,"phases":2424,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":2425,"interventions":2426},[91],[35],[1068,966,1069],{"nctId":1164,"briefTitle":1061,"status":236,"phases":2428,"primaryCompletion":1166,"completion":1166,"start":1167,"enrollment":1168,"conditions":2429,"interventions":2430},[91],[35],[1068,966],{"nctId":2276,"briefTitle":2277,"status":108,"phases":2432,"primaryCompletion":227,"completion":2279,"start":1230,"enrollment":2280,"conditions":2433,"interventions":2434},[91],[1669,1670,26,1671,1672],[1039,1068,2283,2284,1580,2068,2285],{"nctId":1315,"briefTitle":1061,"status":236,"phases":2436,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":1319,"conditions":2437,"interventions":2438},[91],[35],[1068,966],{"nctId":1436,"briefTitle":1437,"status":236,"phases":2440,"primaryCompletion":1166,"completion":1166,"start":1439,"enrollment":1440,"conditions":2441,"interventions":2442},[91],[35],[966,1068],{"trials":2444,"activeCount":100},[],{"trials":2446,"activeCount":100},[],{"intervention":2448,"totalTrials":2409,"cells":2449},"Aripiprazole IM Depot",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2473,"PHASE3":2475,"PHASE4":2498,"NA":2500},{"trials":2451,"activeCount":100},[],{"trials":2453,"activeCount":100},[2454,2462,2466],{"nctId":2455,"briefTitle":2456,"status":108,"phases":2457,"primaryCompletion":2458,"completion":2458,"start":2459,"enrollment":1587,"conditions":2460,"interventions":2461},"NCT01646827","An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia",[89],"2013-04","2012-05",[15],[2448],{"nctId":974,"briefTitle":975,"status":108,"phases":2463,"primaryCompletion":977,"completion":977,"start":978,"enrollment":979,"conditions":2464,"interventions":2465},[89],[15],[982,983],{"nctId":2467,"briefTitle":2468,"status":108,"phases":2469,"primaryCompletion":2470,"completion":2470,"start":326,"enrollment":459,"conditions":2471,"interventions":2472},"NCT01552772","Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole",[89],"2012-04",[15],[2448],{"trials":2474,"activeCount":100},[],{"trials":2476,"activeCount":100},[2477,2484,2491],{"nctId":2478,"briefTitle":2479,"status":108,"phases":2480,"primaryCompletion":449,"completion":1095,"start":1143,"enrollment":2481,"conditions":2482,"interventions":2483},"NCT01663532","Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",[91],340,[15],[2448],{"nctId":2485,"briefTitle":2486,"status":108,"phases":2487,"primaryCompletion":177,"completion":177,"start":2206,"enrollment":2488,"conditions":2489,"interventions":2490},"NCT00731549","Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia",[91],1081,[15],[2448],{"nctId":2492,"briefTitle":2493,"status":108,"phases":2494,"primaryCompletion":1076,"completion":1076,"start":1348,"enrollment":2495,"conditions":2496,"interventions":2497},"NCT01683058","Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia",[91],74,[15],[2448],{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[],{"intervention":2503,"totalTrials":96,"cells":2504},"Centanafadine SR",{"EARLY_PHASE1":2505,"PHASE1":2507,"PHASE2":2518,"PHASE3":2520,"PHASE4":2549,"NA":2551},{"trials":2506,"activeCount":100},[],{"trials":2508,"activeCount":100},[2509],{"nctId":2510,"briefTitle":2511,"status":108,"phases":2512,"primaryCompletion":2513,"completion":2513,"start":2514,"enrollment":967,"conditions":2515,"interventions":2516},"NCT07465731","A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine",[89],"2023-03-26","2022-10-27",[32],[2503,2517],"Centanafadine QD XR",{"trials":2519,"activeCount":100},[],{"trials":2521,"activeCount":100},[2522,2532,2540],{"nctId":2523,"briefTitle":2524,"status":108,"phases":2525,"primaryCompletion":2526,"completion":2526,"start":2527,"enrollment":2528,"conditions":2529,"interventions":2531},"NCT03605836","A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit\u002FHyperactivity Disorder",[91],"2020-05-14","2019-01-16",590,[2530,2340],"Attention Deficit Disorder",[2503,2503],{"nctId":2533,"briefTitle":2534,"status":108,"phases":2535,"primaryCompletion":2536,"completion":2536,"start":2527,"enrollment":2537,"conditions":2538,"interventions":2539},"NCT03605680","A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit\u002FHyperactivity Disorder",[91],"2020-04-11",604,[2530,2340],[2503,2503],{"nctId":2541,"briefTitle":2542,"status":108,"phases":2543,"primaryCompletion":2544,"completion":2544,"start":2545,"enrollment":2546,"conditions":2547,"interventions":2548},"NCT03605849","A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit\u002FHyperactivity Disorder",[91],"2021-09-07","2019-02-14",662,[2530,2340],[2503],{"trials":2550,"activeCount":100},[],{"trials":2552,"activeCount":100},[],{"intervention":1749,"totalTrials":96,"cells":2554},{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2573,"PHASE4":2579,"NA":2581},{"trials":2556,"activeCount":100},[],{"trials":2558,"activeCount":100},[],{"trials":2560,"activeCount":100},[2561,2565,2569],{"nctId":2230,"briefTitle":2231,"status":108,"phases":2562,"primaryCompletion":186,"completion":1261,"start":2233,"enrollment":2234,"conditions":2563,"interventions":2564},[90],[18],[1039,1749],{"nctId":2242,"briefTitle":2243,"status":108,"phases":2566,"primaryCompletion":1366,"completion":1366,"start":2245,"enrollment":2246,"conditions":2567,"interventions":2568},[90],[18],[1749,1039],{"nctId":2260,"briefTitle":2261,"status":108,"phases":2570,"primaryCompletion":1230,"completion":215,"start":1279,"enrollment":2263,"conditions":2571,"interventions":2572},[90],[18],[1039,1749],{"trials":2574,"activeCount":100},[2575],{"nctId":1744,"briefTitle":1745,"status":108,"phases":2576,"primaryCompletion":1723,"completion":1723,"start":177,"enrollment":819,"conditions":2577,"interventions":2578},[91],[35],[1749,1080],{"trials":2580,"activeCount":100},[],{"trials":2582,"activeCount":100},[],{"intervention":1580,"totalTrials":96,"cells":2584},{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2589,"PHASE3":2595,"PHASE4":2609,"NA":2611},{"trials":2586,"activeCount":100},[],{"trials":2588,"activeCount":100},[],{"trials":2590,"activeCount":100},[2591],{"nctId":1571,"briefTitle":1572,"status":108,"phases":2592,"primaryCompletion":1574,"completion":1574,"start":1575,"enrollment":1576,"conditions":2593,"interventions":2594},[90],[1578],[1080,1580],{"trials":2596,"activeCount":100},[2597,2601,2605],{"nctId":2276,"briefTitle":2277,"status":108,"phases":2598,"primaryCompletion":227,"completion":2279,"start":1230,"enrollment":2280,"conditions":2599,"interventions":2600},[91],[1669,1670,26,1671,1672],[1039,1068,2283,2284,1580,2068,2285],{"nctId":1676,"briefTitle":1677,"status":108,"phases":2602,"primaryCompletion":1679,"completion":1680,"start":1681,"enrollment":1682,"conditions":2603,"interventions":2604},[91],[1684],[1080,1580,1080],{"nctId":1712,"briefTitle":1713,"status":108,"phases":2606,"primaryCompletion":1715,"completion":1716,"start":1565,"enrollment":1506,"conditions":2607,"interventions":2608},[91],[1684],[1080,1580],{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[],{"intervention":2614,"totalTrials":240,"cells":2615},"OPC-6535",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2622,"PHASE4":2648,"NA":2650},{"trials":2617,"activeCount":100},[],{"trials":2619,"activeCount":100},[],{"trials":2621,"activeCount":100},[],{"trials":2623,"activeCount":100},[2624,2633,2640],{"nctId":2625,"briefTitle":2626,"status":108,"phases":2627,"primaryCompletion":259,"completion":259,"start":2628,"enrollment":2629,"conditions":2630,"interventions":2632},"NCT00064454","FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis",[91],"2003-05",375,[2631],"Ulcerative Colitis",[2614],{"nctId":2634,"briefTitle":2635,"status":108,"phases":2636,"primaryCompletion":2637,"completion":2637,"start":2628,"enrollment":2629,"conditions":2638,"interventions":2639},"NCT00064441","FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis",[91],"2006-05",[2631],[2614],{"nctId":2641,"briefTitle":2642,"status":108,"phases":2643,"completion":1054,"start":319,"enrollment":2644,"conditions":2645,"interventions":2646},"NCT00092508","CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission",[91],1725,[2631],[2614,2647],"Asacol®",{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[],{"intervention":2653,"totalTrials":146,"cells":2654},"OPC-34712 + ADT",{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2661,"PHASE4":2678,"NA":2680},{"trials":2656,"activeCount":100},[],{"trials":2658,"activeCount":100},[],{"trials":2660,"activeCount":100},[],{"trials":2662,"activeCount":100},[2663,2671],{"nctId":2664,"briefTitle":2665,"status":108,"phases":2666,"primaryCompletion":344,"completion":2667,"start":1243,"enrollment":2668,"conditions":2669,"interventions":2670},"NCT01360645","Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)",[91],"2013-06",826,[1669,1670,26,1671,1672],[2653],{"nctId":2672,"briefTitle":2673,"status":108,"phases":2674,"primaryCompletion":449,"completion":1095,"start":2197,"enrollment":2675,"conditions":2676,"interventions":2677},"NCT01360632","Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)",[91],1539,[1669,1670,26,1671,1672],[2653],{"trials":2679,"activeCount":100},[],{"trials":2681,"activeCount":100},[],{"intervention":2068,"totalTrials":146,"cells":2683},{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2692,"PHASE3":2694,"PHASE4":2700,"NA":2702},{"trials":2685,"activeCount":100},[],{"trials":2687,"activeCount":100},[2688],{"nctId":2058,"briefTitle":2059,"status":108,"phases":2689,"primaryCompletion":396,"completion":2061,"start":2062,"enrollment":2063,"conditions":2690,"interventions":2691},[89],[2065],[2050,2067,2068],{"trials":2693,"activeCount":100},[],{"trials":2695,"activeCount":100},[2696],{"nctId":2276,"briefTitle":2277,"status":108,"phases":2697,"primaryCompletion":227,"completion":2279,"start":1230,"enrollment":2280,"conditions":2698,"interventions":2699},[91],[1669,1670,26,1671,1672],[1039,1068,2283,2284,1580,2068,2285],{"trials":2701,"activeCount":100},[],{"trials":2703,"activeCount":100},[],{"intervention":2705,"totalTrials":146,"cells":2706},"Rebamipide",{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2711,"PHASE3":2713,"PHASE4":2728,"NA":2730},{"trials":2708,"activeCount":100},[],{"trials":2710,"activeCount":100},[],{"trials":2712,"activeCount":100},[],{"trials":2714,"activeCount":100},[2715,2723],{"nctId":2716,"briefTitle":2717,"status":108,"phases":2718,"completion":1008,"start":319,"enrollment":2719,"conditions":2720,"interventions":2722},"NCT00201981","Study of Rebamipide Eye Drops to Treat Dry Eye",[91],740,[2721],"Keratoconjunctivitis Sicca",[2705],{"nctId":2724,"briefTitle":2717,"status":108,"phases":2725,"completion":259,"start":319,"enrollment":2719,"conditions":2726,"interventions":2727},"NCT00201955",[91],[2721],[2705],{"trials":2729,"activeCount":100},[],{"trials":2731,"activeCount":100},[],{"intervention":2733,"totalTrials":146,"cells":2734},"SEP363856",{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2748,"PHASE3":2750,"PHASE4":2762,"NA":2764},{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[2739],{"nctId":2740,"briefTitle":2741,"status":108,"phases":2742,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":385,"conditions":2745,"interventions":2747},"NCT05015673","This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.",[89],"2015-05-26","2014-06-05",[2746],"Narcolepsy",[2733],{"trials":2749,"activeCount":100},[],{"trials":2751,"activeCount":100},[2752],{"nctId":2753,"briefTitle":2754,"status":108,"phases":2755,"primaryCompletion":2756,"completion":2756,"start":2757,"enrollment":2758,"conditions":2759,"interventions":2760},"NCT04115319","A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.",[91],"2022-12-30","2019-11-21",305,[15],[2733,2761],"quetiapine XR",{"trials":2763,"activeCount":100},[],{"trials":2765,"activeCount":100},[],{"intervention":2767,"totalTrials":146,"cells":2768},"Brexpiprazole, OPC-34712",{"EARLY_PHASE1":2769,"PHASE1":2771,"PHASE2":2773,"PHASE3":2775,"PHASE4":2796,"NA":2798},{"trials":2770,"activeCount":100},[],{"trials":2772,"activeCount":100},[],{"trials":2774,"activeCount":100},[],{"trials":2776,"activeCount":100},[2777,2788],{"nctId":2778,"briefTitle":2779,"status":108,"phases":2780,"primaryCompletion":2781,"completion":2781,"start":2782,"enrollment":2783,"conditions":2784,"interventions":2787},"NCT01862640","A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation",[91],"2017-03-15","2013-07-11",433,[2785,1118,2786,29,1046],"Agitation Associated With","Alzheimer's Type",[2767],{"nctId":2789,"briefTitle":2790,"status":108,"phases":2791,"primaryCompletion":2792,"completion":2792,"start":1095,"enrollment":2793,"conditions":2794,"interventions":2795},"NCT01922258","Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",[91],"2017-03",270,[2785,1118,2786,29,1046],[2767],{"trials":2797,"activeCount":100},[],{"trials":2799,"activeCount":100},[],{"intervention":2801,"totalTrials":146,"cells":2802},"Centanafadine Hydrochloride",{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2807,"PHASE3":2809,"PHASE4":2830,"NA":2832},{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[],{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[2811,2820],{"nctId":2812,"briefTitle":2813,"status":108,"phases":2814,"primaryCompletion":2815,"completion":2815,"start":2816,"enrollment":2817,"conditions":2818,"interventions":2819},"NCT05279313","A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit\u002FHyperactivity Disorder.",[91],"2026-04-24","2022-02-24",680,[2389],[2801],{"nctId":2821,"briefTitle":2822,"status":108,"phases":2823,"primaryCompletion":2824,"completion":2825,"start":2826,"enrollment":1036,"conditions":2827,"interventions":2829},"NCT05257265","A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit\u002FHyperactivity Disorder",[91],"2023-09-29","2023-10-05","2022-02-02",[2828],"Attention-Deficit\u002FHyperactivity Disorder",[2801],{"trials":2831,"activeCount":100},[],{"trials":2833,"activeCount":100},[],{"intervention":2835,"totalTrials":146,"cells":2836},"SEP-363856 75mg",{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2843,"PHASE4":2865,"NA":2867},{"trials":2838,"activeCount":100},[],{"trials":2840,"activeCount":100},[],{"trials":2842,"activeCount":100},[],{"trials":2844,"activeCount":100},[2845,2855],{"nctId":2846,"briefTitle":2847,"status":108,"phases":2848,"primaryCompletion":2849,"completion":2849,"start":2850,"enrollment":2851,"conditions":2852,"interventions":2853},"NCT04092686","A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia",[91],"2023-06-14","2019-09-30",464,[15],[2835,2854],"SEP-363856 100mg",{"nctId":2856,"briefTitle":2857,"status":108,"phases":2858,"primaryCompletion":2859,"completion":2860,"start":2861,"enrollment":554,"conditions":2862,"interventions":2863},"NCT04072354","A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia",[91],"2023-05-12","2023-09-12","2019-09-17",[15],[2864,2835],"SEP-363856 50mg",{"trials":2866,"activeCount":100},[],{"trials":2868,"activeCount":100},[],{"intervention":2870,"totalTrials":146,"cells":2871},"AVP-786-28",{"EARLY_PHASE1":2872,"PHASE1":2874,"PHASE2":2876,"PHASE3":2890,"PHASE4":2903,"NA":2905},{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[],{"trials":2877,"activeCount":100},[2878],{"nctId":2879,"briefTitle":2880,"status":108,"phases":2881,"primaryCompletion":2882,"completion":2883,"start":2884,"enrollment":2885,"conditions":2886,"interventions":2888},"NCT03095066","Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury",[90],"2022-08-22","2022-08-31","2017-05-30",168,[2887],"Neurobehavioral Disinhibition",[2870,2889],"AVP-786-42.63",{"trials":2891,"activeCount":100},[2892],{"nctId":2893,"briefTitle":2894,"status":108,"phases":2895,"primaryCompletion":2896,"completion":2897,"start":2898,"enrollment":536,"conditions":2899,"interventions":2901},"NCT02442778","Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type",[91],"2019-08-14","2019-09-09","2015-11-11",[2900],"Agitation in Participants With Dementia of the Alzheimer's Type",[2902,2870,2889],"AVP-786-18",{"trials":2904,"activeCount":100},[],{"trials":2906,"activeCount":100},[],{"intervention":2889,"totalTrials":146,"cells":2908},{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2919,"PHASE4":2925,"NA":2927},{"trials":2910,"activeCount":100},[],{"trials":2912,"activeCount":100},[],{"trials":2914,"activeCount":100},[2915],{"nctId":2879,"briefTitle":2880,"status":108,"phases":2916,"primaryCompletion":2882,"completion":2883,"start":2884,"enrollment":2885,"conditions":2917,"interventions":2918},[90],[2887],[2870,2889],{"trials":2920,"activeCount":100},[2921],{"nctId":2893,"briefTitle":2894,"status":108,"phases":2922,"primaryCompletion":2896,"completion":2897,"start":2898,"enrollment":536,"conditions":2923,"interventions":2924},[91],[2900],[2902,2870,2889],{"trials":2926,"activeCount":100},[],{"trials":2928,"activeCount":100},[],{"intervention":2930,"totalTrials":146,"cells":2931},"Aripiprazole (Abilify®) IM Depot",{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2952,"NA":2954},{"trials":2933,"activeCount":100},[],{"trials":2935,"activeCount":100},[],{"trials":2937,"activeCount":100},[],{"trials":2939,"activeCount":100},[2940,2947],{"nctId":2941,"briefTitle":2942,"status":236,"phases":2943,"primaryCompletion":1143,"completion":1143,"start":326,"enrollment":178,"conditions":2944,"interventions":2945},"NCT01509053","Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole",[91],[15],[2930,2946],"Oral aripiprazole",{"nctId":2948,"briefTitle":2942,"status":108,"phases":2949,"primaryCompletion":1242,"completion":1242,"start":2254,"enrollment":1232,"conditions":2950,"interventions":2951},"NCT01432444",[91],[15],[2930],{"trials":2953,"activeCount":100},[],{"trials":2955,"activeCount":100},[],{"intervention":2957,"totalTrials":379,"cells":2958},"Intramuscular (IM) Depot Aripiprazole",{"EARLY_PHASE1":2959,"PHASE1":2961,"PHASE2":2963,"PHASE3":2965,"PHASE4":2976,"NA":2978},{"trials":2960,"activeCount":100},[],{"trials":2962,"activeCount":100},[],{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[2967],{"nctId":2968,"briefTitle":2969,"status":108,"phases":2970,"primaryCompletion":1771,"completion":1771,"start":2971,"enrollment":2972,"conditions":2973,"interventions":2974},"NCT01567527","Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients",[91],"2012-08",731,[23],[2957,2975],"Intramuscular (IM) Depot Placebo",{"trials":2977,"activeCount":100},[],{"trials":2979,"activeCount":100},[],{"intervention":2975,"totalTrials":379,"cells":2981},{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2988,"PHASE4":2994,"NA":2996},{"trials":2983,"activeCount":100},[],{"trials":2985,"activeCount":100},[],{"trials":2987,"activeCount":100},[],{"trials":2989,"activeCount":100},[2990],{"nctId":2968,"briefTitle":2969,"status":108,"phases":2991,"primaryCompletion":1771,"completion":1771,"start":2971,"enrollment":2972,"conditions":2992,"interventions":2993},[91],[23],[2957,2975],{"trials":2995,"activeCount":100},[],{"trials":2997,"activeCount":100},[],{"intervention":1069,"totalTrials":379,"cells":2999},{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3004,"PHASE3":3006,"PHASE4":3012,"NA":3014},{"trials":3001,"activeCount":100},[],{"trials":3003,"activeCount":100},[],{"trials":3005,"activeCount":100},[],{"trials":3007,"activeCount":100},[3008],{"nctId":1060,"briefTitle":1061,"status":236,"phases":3009,"primaryCompletion":1063,"completion":1063,"start":1064,"enrollment":1065,"conditions":3010,"interventions":3011},[91],[35],[1068,966,1069],{"trials":3013,"activeCount":100},[],{"trials":3015,"activeCount":100},[],{"intervention":1605,"totalTrials":379,"cells":3017},{"EARLY_PHASE1":3018,"PHASE1":3020,"PHASE2":3022,"PHASE3":3024,"PHASE4":3030,"NA":3032},{"trials":3019,"activeCount":100},[],{"trials":3021,"activeCount":100},[],{"trials":3023,"activeCount":100},[],{"trials":3025,"activeCount":100},[3026],{"nctId":1596,"briefTitle":1597,"status":108,"phases":3027,"primaryCompletion":1599,"completion":1600,"start":1601,"enrollment":1602,"conditions":3028,"interventions":3029},[91],[18],[1080,1605],{"trials":3031,"activeCount":100},[],{"trials":3033,"activeCount":100},[],{"intervention":3035,"totalTrials":379,"cells":3036},"Antidepressant + Aripiprazole",{"EARLY_PHASE1":3037,"PHASE1":3039,"PHASE2":3041,"PHASE3":3043,"PHASE4":3052,"NA":3054},{"trials":3038,"activeCount":100},[],{"trials":3040,"activeCount":100},[],{"trials":3042,"activeCount":100},[],{"trials":3044,"activeCount":100},[3045],{"nctId":3046,"briefTitle":3047,"status":108,"phases":3048,"primaryCompletion":978,"completion":978,"start":1271,"enrollment":3049,"conditions":3050,"interventions":3051},"NCT00095745","A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder",[91],1002,[18],[3035],{"trials":3053,"activeCount":100},[],{"trials":3055,"activeCount":100},[],{"intervention":3057,"totalTrials":379,"cells":3058},"Aripiprazole depot 300 or 400 mg",{"EARLY_PHASE1":3059,"PHASE1":3061,"PHASE2":3063,"PHASE3":3065,"PHASE4":3076,"NA":3078},{"trials":3060,"activeCount":100},[],{"trials":3062,"activeCount":100},[],{"trials":3064,"activeCount":100},[],{"trials":3066,"activeCount":100},[3067],{"nctId":3068,"briefTitle":2486,"status":108,"phases":3069,"primaryCompletion":2971,"completion":2971,"start":3070,"enrollment":3071,"conditions":3072,"interventions":3073},"NCT00706654",[91],"2008-09",937,[15],[3057,3074,3075],"Aripiprazole 10-30 mg orally","Aripiprazole depot 25 or 50 mg",{"trials":3077,"activeCount":100},[],{"trials":3079,"activeCount":100},[],{"intervention":3074,"totalTrials":379,"cells":3081},{"EARLY_PHASE1":3082,"PHASE1":3084,"PHASE2":3086,"PHASE3":3088,"PHASE4":3094,"NA":3096},{"trials":3083,"activeCount":100},[],{"trials":3085,"activeCount":100},[],{"trials":3087,"activeCount":100},[],{"trials":3089,"activeCount":100},[3090],{"nctId":3068,"briefTitle":2486,"status":108,"phases":3091,"primaryCompletion":2971,"completion":2971,"start":3070,"enrollment":3071,"conditions":3092,"interventions":3093},[91],[15],[3057,3074,3075],{"trials":3095,"activeCount":100},[],{"trials":3097,"activeCount":100},[],{"intervention":3075,"totalTrials":379,"cells":3099},{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3104,"PHASE3":3106,"PHASE4":3112,"NA":3114},{"trials":3101,"activeCount":100},[],{"trials":3103,"activeCount":100},[],{"trials":3105,"activeCount":100},[],{"trials":3107,"activeCount":100},[3108],{"nctId":3068,"briefTitle":2486,"status":108,"phases":3109,"primaryCompletion":2971,"completion":2971,"start":3070,"enrollment":3071,"conditions":3110,"interventions":3111},[91],[15],[3057,3074,3075],{"trials":3113,"activeCount":100},[],{"trials":3115,"activeCount":100},[],{"intervention":1236,"totalTrials":379,"cells":3117},{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3124,"PHASE4":3130,"NA":3132},{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[],{"trials":3123,"activeCount":100},[],{"trials":3125,"activeCount":100},[3126],{"nctId":1227,"briefTitle":1228,"status":108,"phases":3127,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":3128,"interventions":3129},[91],[1234],[966,1236,1237],{"trials":3131,"activeCount":100},[],{"trials":3133,"activeCount":100},[],{"intervention":1237,"totalTrials":379,"cells":3135},{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3142,"PHASE4":3148,"NA":3150},{"trials":3137,"activeCount":100},[],{"trials":3139,"activeCount":100},[],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[3144],{"nctId":1227,"briefTitle":1228,"status":108,"phases":3145,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":3146,"interventions":3147},[91],[1234],[966,1236,1237],{"trials":3149,"activeCount":100},[],{"trials":3151,"activeCount":100},[],{"intervention":254,"totalTrials":379,"cells":3153},{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3160,"PHASE4":3166,"NA":3168},{"trials":3155,"activeCount":100},[],{"trials":3157,"activeCount":100},[],{"trials":3159,"activeCount":100},[],{"trials":3161,"activeCount":100},[3162],{"nctId":245,"briefTitle":246,"status":108,"phases":3163,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":3164,"interventions":3165},[91],[252],[152,254],{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[],{"intervention":2854,"totalTrials":379,"cells":3171},{"EARLY_PHASE1":3172,"PHASE1":3174,"PHASE2":3176,"PHASE3":3178,"PHASE4":3184,"NA":3186},{"trials":3173,"activeCount":100},[],{"trials":3175,"activeCount":100},[],{"trials":3177,"activeCount":100},[],{"trials":3179,"activeCount":100},[3180],{"nctId":2846,"briefTitle":2847,"status":108,"phases":3181,"primaryCompletion":2849,"completion":2849,"start":2850,"enrollment":2851,"conditions":3182,"interventions":3183},[91],[15],[2835,2854],{"trials":3185,"activeCount":100},[],{"trials":3187,"activeCount":100},[],{"intervention":1285,"totalTrials":379,"cells":3189},{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3194,"PHASE3":3196,"PHASE4":3202,"NA":3204},{"trials":3191,"activeCount":100},[],{"trials":3193,"activeCount":100},[],{"trials":3195,"activeCount":100},[],{"trials":3197,"activeCount":100},[3198],{"nctId":1276,"briefTitle":1277,"status":236,"phases":3199,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":3200,"interventions":3201},[91],[15,1214,23,1283],[966,1285],{"trials":3203,"activeCount":100},[],{"trials":3205,"activeCount":100},[],{"intervention":2283,"totalTrials":379,"cells":3207},{"EARLY_PHASE1":3208,"PHASE1":3210,"PHASE2":3212,"PHASE3":3214,"PHASE4":3220,"NA":3222},{"trials":3209,"activeCount":100},[],{"trials":3211,"activeCount":100},[],{"trials":3213,"activeCount":100},[],{"trials":3215,"activeCount":100},[3216],{"nctId":2276,"briefTitle":2277,"status":108,"phases":3217,"primaryCompletion":227,"completion":2279,"start":1230,"enrollment":2280,"conditions":3218,"interventions":3219},[91],[1669,1670,26,1671,1672],[1039,1068,2283,2284,1580,2068,2285],{"trials":3221,"activeCount":100},[],{"trials":3223,"activeCount":100},[],{"intervention":2284,"totalTrials":379,"cells":3225},{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3232,"PHASE4":3238,"NA":3240},{"trials":3227,"activeCount":100},[],{"trials":3229,"activeCount":100},[],{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[3234],{"nctId":2276,"briefTitle":2277,"status":108,"phases":3235,"primaryCompletion":227,"completion":2279,"start":1230,"enrollment":2280,"conditions":3236,"interventions":3237},[91],[1669,1670,26,1671,1672],[1039,1068,2283,2284,1580,2068,2285],{"trials":3239,"activeCount":100},[],{"trials":3241,"activeCount":100},[],{"intervention":2285,"totalTrials":379,"cells":3243},{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3250,"PHASE4":3256,"NA":3258},{"trials":3245,"activeCount":100},[],{"trials":3247,"activeCount":100},[],{"trials":3249,"activeCount":100},[],{"trials":3251,"activeCount":100},[3252],{"nctId":2276,"briefTitle":2277,"status":108,"phases":3253,"primaryCompletion":227,"completion":2279,"start":1230,"enrollment":2280,"conditions":3254,"interventions":3255},[91],[1669,1670,26,1671,1672],[1039,1068,2283,2284,1580,2068,2285],{"trials":3257,"activeCount":100},[],{"trials":3259,"activeCount":100},[],{"intervention":3261,"totalTrials":379,"cells":3262},"Brexpiprazole +ADT",{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3267,"PHASE3":3269,"PHASE4":3279,"NA":3281},{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[],{"trials":3268,"activeCount":100},[],{"trials":3270,"activeCount":100},[3271],{"nctId":3272,"briefTitle":3273,"status":108,"phases":3274,"primaryCompletion":1771,"completion":3275,"start":1075,"enrollment":3276,"conditions":3277,"interventions":3278},"NCT02196506","Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress",[91],"2016-05",837,[1669,1670,26,1671,1672],[3261],{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"intervention":2902,"totalTrials":379,"cells":3284},{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3291,"PHASE4":3297,"NA":3299},{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[],{"trials":3290,"activeCount":100},[],{"trials":3292,"activeCount":100},[3293],{"nctId":2893,"briefTitle":2894,"status":108,"phases":3294,"primaryCompletion":2896,"completion":2897,"start":2898,"enrollment":536,"conditions":3295,"interventions":3296},[91],[2900],[2902,2870,2889],{"trials":3298,"activeCount":100},[],{"trials":3300,"activeCount":100},[],{"intervention":1674,"totalTrials":379,"cells":3302},{"EARLY_PHASE1":3303,"PHASE1":3305,"PHASE2":3307,"PHASE3":3309,"PHASE4":3315,"NA":3317},{"trials":3304,"activeCount":100},[],{"trials":3306,"activeCount":100},[],{"trials":3308,"activeCount":100},[],{"trials":3310,"activeCount":100},[3311],{"nctId":1662,"briefTitle":1663,"status":108,"phases":3312,"primaryCompletion":1665,"completion":1666,"start":1366,"enrollment":1667,"conditions":3313,"interventions":3314},[91],[1669,1670,26,1671,1672],[1080,1674],{"trials":3316,"activeCount":100},[],{"trials":3318,"activeCount":100},[],{"intervention":2761,"totalTrials":379,"cells":3320},{"EARLY_PHASE1":3321,"PHASE1":3323,"PHASE2":3325,"PHASE3":3327,"PHASE4":3333,"NA":3335},{"trials":3322,"activeCount":100},[],{"trials":3324,"activeCount":100},[],{"trials":3326,"activeCount":100},[],{"trials":3328,"activeCount":100},[3329],{"nctId":2753,"briefTitle":2754,"status":108,"phases":3330,"primaryCompletion":2756,"completion":2756,"start":2757,"enrollment":2758,"conditions":3331,"interventions":3332},[91],[15],[2733,2761],{"trials":3334,"activeCount":100},[],{"trials":3336,"activeCount":100},[],{"intervention":2946,"totalTrials":379,"cells":3338},{"EARLY_PHASE1":3339,"PHASE1":3341,"PHASE2":3343,"PHASE3":3345,"PHASE4":3351,"NA":3353},{"trials":3340,"activeCount":100},[],{"trials":3342,"activeCount":100},[],{"trials":3344,"activeCount":100},[],{"trials":3346,"activeCount":100},[3347],{"nctId":2941,"briefTitle":2942,"status":236,"phases":3348,"primaryCompletion":1143,"completion":1143,"start":326,"enrollment":178,"conditions":3349,"interventions":3350},[91],[15],[2930,2946],{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":100},[],{"intervention":3356,"totalTrials":379,"cells":3357},"OPC-34712 [Brexpiprazole] High Dose",{"EARLY_PHASE1":3358,"PHASE1":3360,"PHASE2":3362,"PHASE3":3364,"PHASE4":3375,"NA":3377},{"trials":3359,"activeCount":100},[],{"trials":3361,"activeCount":100},[],{"trials":3363,"activeCount":100},[],{"trials":3365,"activeCount":100},[3366],{"nctId":3367,"briefTitle":3368,"status":108,"phases":3369,"primaryCompletion":2062,"completion":2062,"start":1243,"enrollment":3370,"conditions":3371,"interventions":3372},"NCT01396421","Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia",[91],636,[1613],[3356,3373,3374],"Experimental: OPC-34712 [Brexpiprazole] Middle Dose","Experimental: OPC-34712 [Brexpiprazole] Low Dose",{"trials":3376,"activeCount":100},[],{"trials":3378,"activeCount":100},[],{"intervention":3373,"totalTrials":379,"cells":3380},{"EARLY_PHASE1":3381,"PHASE1":3383,"PHASE2":3385,"PHASE3":3387,"PHASE4":3393,"NA":3395},{"trials":3382,"activeCount":100},[],{"trials":3384,"activeCount":100},[],{"trials":3386,"activeCount":100},[],{"trials":3388,"activeCount":100},[3389],{"nctId":3367,"briefTitle":3368,"status":108,"phases":3390,"primaryCompletion":2062,"completion":2062,"start":1243,"enrollment":3370,"conditions":3391,"interventions":3392},[91],[1613],[3356,3373,3374],{"trials":3394,"activeCount":100},[],{"trials":3396,"activeCount":100},[],{"intervention":3374,"totalTrials":379,"cells":3398},{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3405,"PHASE4":3411,"NA":3413},{"trials":3400,"activeCount":100},[],{"trials":3402,"activeCount":100},[],{"trials":3404,"activeCount":100},[],{"trials":3406,"activeCount":100},[3407],{"nctId":3367,"briefTitle":3368,"status":108,"phases":3408,"primaryCompletion":2062,"completion":2062,"start":1243,"enrollment":3370,"conditions":3409,"interventions":3410},[91],[1613],[3356,3373,3374],{"trials":3412,"activeCount":100},[],{"trials":3414,"activeCount":100},[],{"intervention":3416,"totalTrials":379,"cells":3417},"Aripiprazole+ ADT",{"EARLY_PHASE1":3418,"PHASE1":3420,"PHASE2":3422,"PHASE3":3424,"PHASE4":3434,"NA":3436},{"trials":3419,"activeCount":100},[],{"trials":3421,"activeCount":100},[],{"trials":3423,"activeCount":100},[],{"trials":3425,"activeCount":100},[3426],{"nctId":3427,"briefTitle":3428,"status":108,"phases":3429,"primaryCompletion":3430,"completion":3430,"start":1113,"enrollment":3431,"conditions":3432,"interventions":3433},"NCT00105196","A Study of Aripiprazole in Patients With Major Depressive Disorder",[91],"2008-03",349,[18],[3416],{"trials":3435,"activeCount":100},[],{"trials":3437,"activeCount":100},[],{"intervention":2864,"totalTrials":379,"cells":3439},{"EARLY_PHASE1":3440,"PHASE1":3442,"PHASE2":3444,"PHASE3":3446,"PHASE4":3452,"NA":3454},{"trials":3441,"activeCount":100},[],{"trials":3443,"activeCount":100},[],{"trials":3445,"activeCount":100},[],{"trials":3447,"activeCount":100},[3448],{"nctId":2856,"briefTitle":2857,"status":108,"phases":3449,"primaryCompletion":2859,"completion":2860,"start":2861,"enrollment":554,"conditions":3450,"interventions":3451},[91],[15],[2864,2835],{"trials":3453,"activeCount":100},[],{"trials":3455,"activeCount":100},[],{"intervention":1343,"totalTrials":379,"cells":3457},{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3462,"PHASE3":3464,"PHASE4":3470,"NA":3472},{"trials":3459,"activeCount":100},[],{"trials":3461,"activeCount":100},[],{"trials":3463,"activeCount":100},[],{"trials":3465,"activeCount":100},[3466],{"nctId":1338,"briefTitle":1339,"status":108,"phases":3467,"primaryCompletion":327,"completion":327,"start":166,"enrollment":1056,"conditions":3468,"interventions":3469},[91],[21],[966,1343],{"trials":3471,"activeCount":100},[],{"trials":3473,"activeCount":100},[],{"intervention":3475,"totalTrials":379,"cells":3476},"Aripiprazole tablet, 10 mg",{"EARLY_PHASE1":3477,"PHASE1":3479,"PHASE2":3481,"PHASE3":3483,"PHASE4":3493,"NA":3495},{"trials":3478,"activeCount":100},[],{"trials":3480,"activeCount":100},[],{"trials":3482,"activeCount":100},[],{"trials":3484,"activeCount":100},[3485],{"nctId":3486,"briefTitle":3487,"status":108,"phases":3488,"primaryCompletion":1209,"completion":1209,"start":196,"enrollment":3489,"conditions":3490,"interventions":3491},"NCT00102063","Aripiprazole in Adolescents With Schizophrenia",[91],302,[15],[3475,3492],"Aripiprazole tablet, 30 mg",{"trials":3494,"activeCount":100},[],{"trials":3496,"activeCount":100},[],{"intervention":3492,"totalTrials":379,"cells":3498},{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3505,"PHASE4":3511,"NA":3513},{"trials":3500,"activeCount":100},[],{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[],{"trials":3506,"activeCount":100},[3507],{"nctId":3486,"briefTitle":3487,"status":108,"phases":3508,"primaryCompletion":1209,"completion":1209,"start":196,"enrollment":3489,"conditions":3509,"interventions":3510},[91],[15],[3475,3492],{"trials":3512,"activeCount":100},[],{"trials":3514,"activeCount":100},[],{"intervention":1394,"totalTrials":379,"cells":3516},{"EARLY_PHASE1":3517,"PHASE1":3519,"PHASE2":3521,"PHASE3":3523,"PHASE4":3529,"NA":3531},{"trials":3518,"activeCount":100},[],{"trials":3520,"activeCount":100},[],{"trials":3522,"activeCount":100},[],{"trials":3524,"activeCount":100},[3525],{"nctId":1387,"briefTitle":1388,"status":108,"phases":3526,"primaryCompletion":1390,"completion":1390,"start":196,"enrollment":1391,"conditions":3527,"interventions":3528},[91],[15],[966,1394],{"trials":3530,"activeCount":100},[],{"trials":3532,"activeCount":100},[],{"intervention":3534,"totalTrials":379,"cells":3535},"Delamanid + OBR",{"EARLY_PHASE1":3536,"PHASE1":3538,"PHASE2":3540,"PHASE3":3542,"PHASE4":3554,"NA":3556},{"trials":3537,"activeCount":100},[],{"trials":3539,"activeCount":100},[],{"trials":3541,"activeCount":100},[],{"trials":3543,"activeCount":100},[3544],{"nctId":3545,"briefTitle":3546,"status":108,"phases":3547,"primaryCompletion":3548,"completion":3548,"start":3549,"enrollment":3550,"conditions":3551,"interventions":3553},"NCT01424670","Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis",[91],"2016-07-04","2011-09-02",511,[3552],"Multidrug-resistant Tuberculosis",[3534],{"trials":3555,"activeCount":100},[],{"trials":3557,"activeCount":100},[],{"intervention":2647,"totalTrials":379,"cells":3559},{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3566,"PHASE4":3572,"NA":3574},{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[3568],{"nctId":2641,"briefTitle":2642,"status":108,"phases":3569,"completion":1054,"start":319,"enrollment":2644,"conditions":3570,"interventions":3571},[91],[2631],[2614,2647],{"trials":3573,"activeCount":100},[],{"trials":3575,"activeCount":100},[],{"intervention":3577,"totalTrials":379,"cells":3578},"Aripiprazole depot",{"EARLY_PHASE1":3579,"PHASE1":3581,"PHASE2":3583,"PHASE3":3585,"PHASE4":3596,"NA":3598},{"trials":3580,"activeCount":100},[],{"trials":3582,"activeCount":100},[],{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[3587],{"nctId":3588,"briefTitle":2486,"status":108,"phases":3589,"primaryCompletion":3590,"completion":3591,"start":3592,"enrollment":3593,"conditions":3594,"interventions":3595},"NCT00705783",[91],"2010-08","2011-02","2008-07",843,[15],[3577],{"trials":3597,"activeCount":100},[],{"trials":3599,"activeCount":100},[],{"intervention":3601,"totalTrials":3602,"cells":3603},"Delamanid",5,{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3666,"PHASE4":3668,"NA":3670},{"trials":3605,"activeCount":100},[],{"trials":3607,"activeCount":100},[],{"trials":3609,"activeCount":100},[3610,3620,3634,3646,3657],{"nctId":3611,"briefTitle":3612,"status":236,"phases":3613,"primaryCompletion":3614,"completion":3614,"start":3615,"enrollment":12,"conditions":3616,"interventions":3618},"NCT01131351","Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis",[90],"2011-05-12","2010-02-19",[3617],"Tuberculosis",[3601,3619],"Optimized Background Regimen",{"nctId":3621,"briefTitle":3622,"status":108,"phases":3623,"primaryCompletion":3624,"completion":3625,"start":3626,"enrollment":1784,"conditions":3627,"interventions":3629},"NCT05221502","Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB",[90],"2024-04-08","2024-05-19","2022-04-12",[3628],"Pulmonary TB",[3601,3630,788,3631,3632,3633],"Bedaquiline","RHEZ","Rifampin","Isoniazid",{"nctId":3635,"briefTitle":3636,"status":108,"phases":3637,"primaryCompletion":3638,"completion":3638,"start":3639,"enrollment":3640,"conditions":3641,"interventions":3645},"NCT00685360","A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)",[90],"2010-06-11","2008-05-08",481,[3642,3643,3644],"Tuberculosis, Pulmonary","Tuberculosis, Multidrug Resistant","Extensively Drug-Resistant Tuberculosis",[3601,3619],{"nctId":3647,"briefTitle":3648,"status":108,"phases":3649,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":3652,"conditions":3653,"interventions":3655},"NCT02573350","A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683",[90],"2011-10-27","2009-03-26",213,[3654],"Tuberculosis, Multidrug-Resistant",[3601,3656],"OBR",{"nctId":3658,"briefTitle":3659,"status":108,"phases":3660,"primaryCompletion":1630,"completion":1630,"start":3661,"enrollment":1587,"conditions":3662,"interventions":3664},"NCT01859923","A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)",[90],"2013-07-20",[3663],"Multidrug Resistant Tuberculosis",[3601,3665,3619],"Delamanid Pediatric Formulation",{"trials":3667,"activeCount":100},[],{"trials":3669,"activeCount":100},[],{"trials":3671,"activeCount":100},[],{"intervention":3619,"totalTrials":96,"cells":3673},{"EARLY_PHASE1":3674,"PHASE1":3676,"PHASE2":3693,"PHASE3":3707,"PHASE4":3709,"NA":3711},{"trials":3675,"activeCount":100},[],{"trials":3677,"activeCount":100},[3678],{"nctId":3679,"briefTitle":3680,"status":108,"phases":3681,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":1587,"conditions":3685,"interventions":3687},"NCT01856634","Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis",[89],"2017-12-10","2017-12-28","2013-06-14",[3663,3686],"Pediatric",[3688,3689,3690,3691,3692,3619],"100 mg Delamanid","50 mg Delamanid","25 mg Pediatric Formulation Delamanid","10 mg Delamanid Pediatric Formulation","5 mg Delamanid Pediatric Formulation",{"trials":3694,"activeCount":100},[3695,3699,3703],{"nctId":3611,"briefTitle":3612,"status":236,"phases":3696,"primaryCompletion":3614,"completion":3614,"start":3615,"enrollment":12,"conditions":3697,"interventions":3698},[90],[3617],[3601,3619],{"nctId":3635,"briefTitle":3636,"status":108,"phases":3700,"primaryCompletion":3638,"completion":3638,"start":3639,"enrollment":3640,"conditions":3701,"interventions":3702},[90],[3642,3643,3644],[3601,3619],{"nctId":3658,"briefTitle":3659,"status":108,"phases":3704,"primaryCompletion":1630,"completion":1630,"start":3661,"enrollment":1587,"conditions":3705,"interventions":3706},[90],[3663],[3601,3665,3619],{"trials":3708,"activeCount":100},[],{"trials":3710,"activeCount":100},[],{"trials":3712,"activeCount":100},[],{"intervention":3714,"totalTrials":240,"cells":3715},"CTN SR",{"EARLY_PHASE1":3716,"PHASE1":3718,"PHASE2":3731,"PHASE3":3750,"PHASE4":3752,"NA":3754},{"trials":3717,"activeCount":100},[],{"trials":3719,"activeCount":100},[3720],{"nctId":3721,"briefTitle":3722,"status":108,"phases":3723,"primaryCompletion":3724,"completion":3724,"start":3725,"enrollment":3726,"conditions":3727,"interventions":3729},"NCT07253441","A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels",[89],"2024-12-30","2024-08-29",174,[3728],"Attention Deficit Disorder With Hyperactivity",[3730,3714,3730],"CTN XR",{"trials":3732,"activeCount":100},[3733,3742],{"nctId":3734,"briefTitle":3735,"status":108,"phases":3736,"primaryCompletion":3737,"completion":3737,"start":3738,"enrollment":2199,"conditions":3739,"interventions":3741},"NCT01939353","Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder",[90],"2014-02-20","2013-10-03",[3740],"Adult ADHD",[3714],{"nctId":3743,"briefTitle":3744,"status":108,"phases":3745,"primaryCompletion":3746,"completion":3746,"start":3747,"enrollment":1377,"conditions":3748,"interventions":3749},"NCT02547428","Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)",[90],"2016-06-04","2015-08-03",[3728],[3714],{"trials":3751,"activeCount":100},[],{"trials":3753,"activeCount":100},[],{"trials":3755,"activeCount":100},[],{"intervention":3757,"totalTrials":146,"cells":3758},"OPA-15406",{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3772,"PHASE3":3785,"PHASE4":3787,"NA":3789},{"trials":3760,"activeCount":100},[],{"trials":3762,"activeCount":100},[3763],{"nctId":3764,"briefTitle":3765,"status":108,"phases":3766,"primaryCompletion":1242,"completion":1242,"start":2971,"enrollment":3767,"conditions":3768,"interventions":3770},"NCT01702181","A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis",[89],92,[3769],"Atopic Dermatitis",[3757,3771],"Tacrolimus",{"trials":3773,"activeCount":100},[3774],{"nctId":3775,"briefTitle":3776,"status":108,"phases":3777,"primaryCompletion":3778,"completion":3779,"start":3780,"enrollment":3781,"conditions":3782,"interventions":3783},"NCT02068352","A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis",[90],"2015-01-28","2015-02-03","2014-06-20",121,[3769],[3757,3784],"Vehicle ointment",{"trials":3786,"activeCount":100},[],{"trials":3788,"activeCount":100},[],{"trials":3790,"activeCount":100},[],{"intervention":788,"totalTrials":146,"cells":3792},{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3801,"PHASE3":3807,"PHASE4":3809,"NA":3811},{"trials":3794,"activeCount":100},[],{"trials":3796,"activeCount":100},[3797],{"nctId":779,"briefTitle":780,"status":108,"phases":3798,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":3799,"interventions":3800},[89],[32],[788,789,755],{"trials":3802,"activeCount":100},[3803],{"nctId":3621,"briefTitle":3622,"status":108,"phases":3804,"primaryCompletion":3624,"completion":3625,"start":3626,"enrollment":1784,"conditions":3805,"interventions":3806},[90],[3628],[3601,3630,788,3631,3632,3633],{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[],{"trials":3812,"activeCount":100},[],{"intervention":3631,"totalTrials":146,"cells":3814},{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3819,"PHASE3":3841,"PHASE4":3843,"NA":3845},{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":100},[],{"trials":3820,"activeCount":100},[3821,3825],{"nctId":3621,"briefTitle":3622,"status":108,"phases":3822,"primaryCompletion":3624,"completion":3625,"start":3626,"enrollment":1784,"conditions":3823,"interventions":3824},[90],[3628],[3601,3630,788,3631,3632,3633],{"nctId":3826,"briefTitle":3827,"status":108,"phases":3828,"primaryCompletion":3829,"completion":3830,"start":3831,"enrollment":1784,"conditions":3832,"interventions":3833},"NCT03678688","A Phase 1\u002F2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis",[89,90],"2022-02-14","2022-03-11","2018-10-18",[3628],[3834,3835,3836,3837,3631,3838,3839,3840],"10 mg OPC-167832","30 mg OPC-167832","90 mg OPC-167832","3 mg OPC-167832","30 mg OPC-167832 + 300 mg delamanid","30 mg OPC-167832 + 400 mg BDQ","30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ",{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[],{"intervention":3848,"totalTrials":146,"cells":3849},"Tolvaptan MR",{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3854,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3851,"activeCount":100},[],{"trials":3853,"activeCount":100},[],{"trials":3855,"activeCount":100},[3856,3863],{"nctId":3857,"briefTitle":3858,"status":108,"phases":3859,"primaryCompletion":2197,"completion":2197,"start":216,"enrollment":721,"conditions":3860,"interventions":3861},"NCT01210560","Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD",[90],[219],[3848,3848,3848,3862,3848],"Tolvaptan IR",{"nctId":3864,"briefTitle":3865,"status":108,"phases":3866,"primaryCompletion":3867,"completion":3867,"start":1230,"enrollment":3868,"conditions":3869,"interventions":3870},"NCT01451827","8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[90],"2013-07",178,[219],[3848,3862],{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[],{"trials":3876,"activeCount":100},[],{"intervention":3862,"totalTrials":146,"cells":3878},{"EARLY_PHASE1":3879,"PHASE1":3881,"PHASE2":3883,"PHASE3":3893,"PHASE4":3895,"NA":3897},{"trials":3880,"activeCount":100},[],{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[3885,3889],{"nctId":3857,"briefTitle":3858,"status":108,"phases":3886,"primaryCompletion":2197,"completion":2197,"start":216,"enrollment":721,"conditions":3887,"interventions":3888},[90],[219],[3848,3848,3848,3862,3848],{"nctId":3864,"briefTitle":3865,"status":108,"phases":3890,"primaryCompletion":3867,"completion":3867,"start":1230,"enrollment":3868,"conditions":3891,"interventions":3892},[90],[219],[3848,3862],{"trials":3894,"activeCount":100},[],{"trials":3896,"activeCount":100},[],{"trials":3898,"activeCount":100},[],{"intervention":3784,"totalTrials":379,"cells":3900},{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3911,"PHASE4":3913,"NA":3915},{"trials":3902,"activeCount":100},[],{"trials":3904,"activeCount":100},[],{"trials":3906,"activeCount":100},[3907],{"nctId":3775,"briefTitle":3776,"status":108,"phases":3908,"primaryCompletion":3778,"completion":3779,"start":3780,"enrollment":3781,"conditions":3909,"interventions":3910},[90],[3769],[3757,3784],{"trials":3912,"activeCount":100},[],{"trials":3914,"activeCount":100},[],{"trials":3916,"activeCount":100},[],{"intervention":3630,"totalTrials":379,"cells":3918},{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3929,"PHASE4":3931,"NA":3933},{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[],{"trials":3924,"activeCount":100},[3925],{"nctId":3621,"briefTitle":3622,"status":108,"phases":3926,"primaryCompletion":3624,"completion":3625,"start":3626,"enrollment":1784,"conditions":3927,"interventions":3928},[90],[3628],[3601,3630,788,3631,3632,3633],{"trials":3930,"activeCount":100},[],{"trials":3932,"activeCount":100},[],{"trials":3934,"activeCount":100},[],{"intervention":3632,"totalTrials":379,"cells":3936},{"EARLY_PHASE1":3937,"PHASE1":3939,"PHASE2":3941,"PHASE3":3947,"PHASE4":3949,"NA":3951},{"trials":3938,"activeCount":100},[],{"trials":3940,"activeCount":100},[],{"trials":3942,"activeCount":100},[3943],{"nctId":3621,"briefTitle":3622,"status":108,"phases":3944,"primaryCompletion":3624,"completion":3625,"start":3626,"enrollment":1784,"conditions":3945,"interventions":3946},[90],[3628],[3601,3630,788,3631,3632,3633],{"trials":3948,"activeCount":100},[],{"trials":3950,"activeCount":100},[],{"trials":3952,"activeCount":100},[],{"intervention":3633,"totalTrials":379,"cells":3954},{"EARLY_PHASE1":3955,"PHASE1":3957,"PHASE2":3959,"PHASE3":3965,"PHASE4":3967,"NA":3969},{"trials":3956,"activeCount":100},[],{"trials":3958,"activeCount":100},[],{"trials":3960,"activeCount":100},[3961],{"nctId":3621,"briefTitle":3622,"status":108,"phases":3962,"primaryCompletion":3624,"completion":3625,"start":3626,"enrollment":1784,"conditions":3963,"interventions":3964},[90],[3628],[3601,3630,788,3631,3632,3633],{"trials":3966,"activeCount":100},[],{"trials":3968,"activeCount":100},[],{"trials":3970,"activeCount":100},[],{"intervention":125,"totalTrials":379,"cells":3972},{"EARLY_PHASE1":3973,"PHASE1":3975,"PHASE2":3977,"PHASE3":3983,"PHASE4":3985,"NA":3987},{"trials":3974,"activeCount":100},[],{"trials":3976,"activeCount":100},[],{"trials":3978,"activeCount":100},[3979],{"nctId":116,"briefTitle":117,"status":108,"phases":3980,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":3981,"interventions":3982},[89,90],[123],[125,86],{"trials":3984,"activeCount":100},[],{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[],{"intervention":3834,"totalTrials":379,"cells":3990},{"EARLY_PHASE1":3991,"PHASE1":3993,"PHASE2":3995,"PHASE3":4001,"PHASE4":4003,"NA":4005},{"trials":3992,"activeCount":100},[],{"trials":3994,"activeCount":100},[],{"trials":3996,"activeCount":100},[3997],{"nctId":3826,"briefTitle":3827,"status":108,"phases":3998,"primaryCompletion":3829,"completion":3830,"start":3831,"enrollment":1784,"conditions":3999,"interventions":4000},[89,90],[3628],[3834,3835,3836,3837,3631,3838,3839,3840],{"trials":4002,"activeCount":100},[],{"trials":4004,"activeCount":100},[],{"trials":4006,"activeCount":100},[],{"intervention":3835,"totalTrials":379,"cells":4008},{"EARLY_PHASE1":4009,"PHASE1":4011,"PHASE2":4013,"PHASE3":4019,"PHASE4":4021,"NA":4023},{"trials":4010,"activeCount":100},[],{"trials":4012,"activeCount":100},[],{"trials":4014,"activeCount":100},[4015],{"nctId":3826,"briefTitle":3827,"status":108,"phases":4016,"primaryCompletion":3829,"completion":3830,"start":3831,"enrollment":1784,"conditions":4017,"interventions":4018},[89,90],[3628],[3834,3835,3836,3837,3631,3838,3839,3840],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[],{"intervention":3836,"totalTrials":379,"cells":4026},{"EARLY_PHASE1":4027,"PHASE1":4029,"PHASE2":4031,"PHASE3":4037,"PHASE4":4039,"NA":4041},{"trials":4028,"activeCount":100},[],{"trials":4030,"activeCount":100},[],{"trials":4032,"activeCount":100},[4033],{"nctId":3826,"briefTitle":3827,"status":108,"phases":4034,"primaryCompletion":3829,"completion":3830,"start":3831,"enrollment":1784,"conditions":4035,"interventions":4036},[89,90],[3628],[3834,3835,3836,3837,3631,3838,3839,3840],{"trials":4038,"activeCount":100},[],{"trials":4040,"activeCount":100},[],{"trials":4042,"activeCount":100},[],{"intervention":3837,"totalTrials":379,"cells":4044},{"EARLY_PHASE1":4045,"PHASE1":4047,"PHASE2":4049,"PHASE3":4055,"PHASE4":4057,"NA":4059},{"trials":4046,"activeCount":100},[],{"trials":4048,"activeCount":100},[],{"trials":4050,"activeCount":100},[4051],{"nctId":3826,"briefTitle":3827,"status":108,"phases":4052,"primaryCompletion":3829,"completion":3830,"start":3831,"enrollment":1784,"conditions":4053,"interventions":4054},[89,90],[3628],[3834,3835,3836,3837,3631,3838,3839,3840],{"trials":4056,"activeCount":100},[],{"trials":4058,"activeCount":100},[],{"trials":4060,"activeCount":100},[],{"intervention":3838,"totalTrials":379,"cells":4062},{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4067,"PHASE3":4073,"PHASE4":4075,"NA":4077},{"trials":4064,"activeCount":100},[],{"trials":4066,"activeCount":100},[],{"trials":4068,"activeCount":100},[4069],{"nctId":3826,"briefTitle":3827,"status":108,"phases":4070,"primaryCompletion":3829,"completion":3830,"start":3831,"enrollment":1784,"conditions":4071,"interventions":4072},[89,90],[3628],[3834,3835,3836,3837,3631,3838,3839,3840],{"trials":4074,"activeCount":100},[],{"trials":4076,"activeCount":100},[],{"trials":4078,"activeCount":100},[],{"intervention":3839,"totalTrials":379,"cells":4080},{"EARLY_PHASE1":4081,"PHASE1":4083,"PHASE2":4085,"PHASE3":4091,"PHASE4":4093,"NA":4095},{"trials":4082,"activeCount":100},[],{"trials":4084,"activeCount":100},[],{"trials":4086,"activeCount":100},[4087],{"nctId":3826,"briefTitle":3827,"status":108,"phases":4088,"primaryCompletion":3829,"completion":3830,"start":3831,"enrollment":1784,"conditions":4089,"interventions":4090},[89,90],[3628],[3834,3835,3836,3837,3631,3838,3839,3840],{"trials":4092,"activeCount":100},[],{"trials":4094,"activeCount":100},[],{"trials":4096,"activeCount":100},[],{"intervention":3840,"totalTrials":379,"cells":4098},{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4103,"PHASE3":4109,"PHASE4":4111,"NA":4113},{"trials":4100,"activeCount":100},[],{"trials":4102,"activeCount":100},[],{"trials":4104,"activeCount":100},[4105],{"nctId":3826,"briefTitle":3827,"status":108,"phases":4106,"primaryCompletion":3829,"completion":3830,"start":3831,"enrollment":1784,"conditions":4107,"interventions":4108},[89,90],[3628],[3834,3835,3836,3837,3631,3838,3839,3840],{"trials":4110,"activeCount":100},[],{"trials":4112,"activeCount":100},[],{"trials":4114,"activeCount":100},[],{"intervention":3656,"totalTrials":379,"cells":4116},{"EARLY_PHASE1":4117,"PHASE1":4119,"PHASE2":4121,"PHASE3":4127,"PHASE4":4129,"NA":4131},{"trials":4118,"activeCount":100},[],{"trials":4120,"activeCount":100},[],{"trials":4122,"activeCount":100},[4123],{"nctId":3647,"briefTitle":3648,"status":108,"phases":4124,"primaryCompletion":3650,"completion":3650,"start":3651,"enrollment":3652,"conditions":4125,"interventions":4126},[90],[3654],[3601,3656],{"trials":4128,"activeCount":100},[],{"trials":4130,"activeCount":100},[],{"trials":4132,"activeCount":100},[],{"intervention":4134,"totalTrials":379,"cells":4135},"OPC-131461",{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4140,"PHASE3":4151,"PHASE4":4153,"NA":4155},{"trials":4137,"activeCount":100},[],{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[4142],{"nctId":4143,"briefTitle":4144,"status":298,"phases":4145,"primaryCompletion":4146,"completion":4146,"start":4147,"enrollment":100,"conditions":4148,"interventions":4150},"NCT06795399","A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure",[90],"2025-05-25","2025-04-30",[4149],"Heart Failure",[4134],{"trials":4152,"activeCount":100},[],{"trials":4154,"activeCount":100},[],{"trials":4156,"activeCount":100},[],{"intervention":4158,"totalTrials":379,"cells":4159},"dasatinib",{"EARLY_PHASE1":4160,"PHASE1":4162,"PHASE2":4164,"PHASE3":4174,"PHASE4":4176,"NA":4178},{"trials":4161,"activeCount":100},[],{"trials":4163,"activeCount":100},[],{"trials":4165,"activeCount":100},[4166],{"nctId":4167,"briefTitle":4168,"status":108,"phases":4169,"primaryCompletion":467,"completion":1554,"start":2197,"enrollment":4170,"conditions":4171,"interventions":4173},"NCT01395017","Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer",[90],202,[4172],"Pancreatic Cancer",[4158],{"trials":4175,"activeCount":100},[],{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"intervention":4181,"totalTrials":379,"cells":4182},"tetomilast",{"EARLY_PHASE1":4183,"PHASE1":4185,"PHASE2":4187,"PHASE3":4198,"PHASE4":4200,"NA":4202},{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[],{"trials":4188,"activeCount":100},[4189],{"nctId":4190,"briefTitle":4191,"status":236,"phases":4192,"primaryCompletion":395,"completion":4193,"start":309,"enrollment":4194,"conditions":4195,"interventions":4197},"NCT00874497","Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema",[90],"2015-08",84,[4196],"Chronic Obstructive Pulmonary Disease",[4181],{"trials":4199,"activeCount":100},[],{"trials":4201,"activeCount":100},[],{"trials":4203,"activeCount":100},[],{"intervention":4205,"totalTrials":379,"cells":4206},"Dose-Placebo",{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4228,"PHASE4":4230,"NA":4232},{"trials":4208,"activeCount":100},[],{"trials":4210,"activeCount":100},[],{"trials":4212,"activeCount":100},[4213],{"nctId":4214,"briefTitle":4215,"status":108,"phases":4216,"primaryCompletion":4217,"completion":4218,"start":4219,"enrollment":4220,"conditions":4221,"interventions":4224},"NCT04287985","Safety and Efficacy Study of VIS649 for IgA Nephropathy",[90],"2023-05-19","2023-06-18","2020-07-20",155,[582,4222,4223],"Glomerular Disease","IgAN",[4205,4225,4226,4227],"Low Dose-VIS649","Medium Dose-VIS649","High Dose-VIS649",{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[],{"trials":4233,"activeCount":100},[],{"intervention":4225,"totalTrials":379,"cells":4235},{"EARLY_PHASE1":4236,"PHASE1":4238,"PHASE2":4240,"PHASE3":4246,"PHASE4":4248,"NA":4250},{"trials":4237,"activeCount":100},[],{"trials":4239,"activeCount":100},[],{"trials":4241,"activeCount":100},[4242],{"nctId":4214,"briefTitle":4215,"status":108,"phases":4243,"primaryCompletion":4217,"completion":4218,"start":4219,"enrollment":4220,"conditions":4244,"interventions":4245},[90],[582,4222,4223],[4205,4225,4226,4227],{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[],{"intervention":4226,"totalTrials":379,"cells":4253},{"EARLY_PHASE1":4254,"PHASE1":4256,"PHASE2":4258,"PHASE3":4264,"PHASE4":4266,"NA":4268},{"trials":4255,"activeCount":100},[],{"trials":4257,"activeCount":100},[],{"trials":4259,"activeCount":100},[4260],{"nctId":4214,"briefTitle":4215,"status":108,"phases":4261,"primaryCompletion":4217,"completion":4218,"start":4219,"enrollment":4220,"conditions":4262,"interventions":4263},[90],[582,4222,4223],[4205,4225,4226,4227],{"trials":4265,"activeCount":100},[],{"trials":4267,"activeCount":100},[],{"trials":4269,"activeCount":100},[],{"intervention":4227,"totalTrials":379,"cells":4271},{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4282,"PHASE4":4284,"NA":4286},{"trials":4273,"activeCount":100},[],{"trials":4275,"activeCount":100},[],{"trials":4277,"activeCount":100},[4278],{"nctId":4214,"briefTitle":4215,"status":108,"phases":4279,"primaryCompletion":4217,"completion":4218,"start":4219,"enrollment":4220,"conditions":4280,"interventions":4281},[90],[582,4222,4223],[4205,4225,4226,4227],{"trials":4283,"activeCount":100},[],{"trials":4285,"activeCount":100},[],{"trials":4287,"activeCount":100},[],{"intervention":4289,"totalTrials":379,"cells":4290},"IV busulfan",{"EARLY_PHASE1":4291,"PHASE1":4293,"PHASE2":4295,"PHASE3":4307,"PHASE4":4309,"NA":4311},{"trials":4292,"activeCount":100},[],{"trials":4294,"activeCount":100},[],{"trials":4296,"activeCount":100},[4297],{"nctId":4298,"briefTitle":4299,"status":108,"phases":4300,"primaryCompletion":4301,"completion":4301,"start":4302,"enrollment":178,"conditions":4303,"interventions":4305},"NCT01009840","IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients",[90],"2012-03-01","2010-05-01",[4304],"Multiple Myeloma",[4289,4306],"bortezomib",{"trials":4308,"activeCount":100},[],{"trials":4310,"activeCount":100},[],{"trials":4312,"activeCount":100},[],{"intervention":4306,"totalTrials":379,"cells":4314},{"EARLY_PHASE1":4315,"PHASE1":4317,"PHASE2":4319,"PHASE3":4325,"PHASE4":4327,"NA":4329},{"trials":4316,"activeCount":100},[],{"trials":4318,"activeCount":100},[],{"trials":4320,"activeCount":100},[4321],{"nctId":4298,"briefTitle":4299,"status":108,"phases":4322,"primaryCompletion":4301,"completion":4301,"start":4302,"enrollment":178,"conditions":4323,"interventions":4324},[90],[4304],[4289,4306],{"trials":4326,"activeCount":100},[],{"trials":4328,"activeCount":100},[],{"trials":4330,"activeCount":100},[],{"intervention":4332,"totalTrials":379,"cells":4333},"IV Busulfan, Cyclophosphamide and Etoposide",{"EARLY_PHASE1":4334,"PHASE1":4336,"PHASE2":4338,"PHASE3":4349,"PHASE4":4351,"NA":4353},{"trials":4335,"activeCount":100},[],{"trials":4337,"activeCount":100},[],{"trials":4339,"activeCount":100},[4340],{"nctId":4341,"briefTitle":4342,"status":108,"phases":4343,"primaryCompletion":344,"completion":2667,"start":4344,"enrollment":4345,"conditions":4346,"interventions":4348},"NCT00948090","PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients",[90],"2010-01",207,[4347],"Lymphoma",[4332],{"trials":4350,"activeCount":100},[],{"trials":4352,"activeCount":100},[],{"trials":4354,"activeCount":100},[],{"intervention":4356,"totalTrials":379,"cells":4357},"Aripiprazole + IEM",{"EARLY_PHASE1":4358,"PHASE1":4360,"PHASE2":4362,"PHASE3":4372,"PHASE4":4374,"NA":4376},{"trials":4359,"activeCount":100},[],{"trials":4361,"activeCount":100},[],{"trials":4363,"activeCount":100},[4364],{"nctId":4365,"briefTitle":4366,"status":108,"phases":4367,"primaryCompletion":4368,"completion":4368,"start":4369,"enrollment":1754,"conditions":4370,"interventions":4371},"NCT02722967","Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System",[90],"2016-09","2016-03",[15,18,23],[4356],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[],{"intervention":3665,"totalTrials":379,"cells":4379},{"EARLY_PHASE1":4380,"PHASE1":4382,"PHASE2":4384,"PHASE3":4390,"PHASE4":4392,"NA":4394},{"trials":4381,"activeCount":100},[],{"trials":4383,"activeCount":100},[],{"trials":4385,"activeCount":100},[4386],{"nctId":3658,"briefTitle":3659,"status":108,"phases":4387,"primaryCompletion":1630,"completion":1630,"start":3661,"enrollment":1587,"conditions":4388,"interventions":4389},[90],[3663],[3601,3665,3619],{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"trials":4395,"activeCount":100},[],{"intervention":4397,"totalTrials":379,"cells":4398},"OPC-64005",{"EARLY_PHASE1":4399,"PHASE1":4401,"PHASE2":4403,"PHASE3":4416,"PHASE4":4418,"NA":4420},{"trials":4400,"activeCount":100},[],{"trials":4402,"activeCount":100},[],{"trials":4404,"activeCount":100},[4405],{"nctId":4406,"briefTitle":4407,"status":108,"phases":4408,"primaryCompletion":4409,"completion":4409,"start":4410,"enrollment":4411,"conditions":4412,"interventions":4414},"NCT03324581","The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit\u002FHyperactivity Disorder",[90],"2018-10-31","2017-11-09",239,[4413],"Adult Attention Deficit Hyperactivity Disorder",[4397,4415],"Atomoxetine",{"trials":4417,"activeCount":100},[],{"trials":4419,"activeCount":100},[],{"trials":4421,"activeCount":100},[],{"intervention":4415,"totalTrials":379,"cells":4423},{"EARLY_PHASE1":4424,"PHASE1":4426,"PHASE2":4428,"PHASE3":4434,"PHASE4":4436,"NA":4438},{"trials":4425,"activeCount":100},[],{"trials":4427,"activeCount":100},[],{"trials":4429,"activeCount":100},[4430],{"nctId":4406,"briefTitle":4407,"status":108,"phases":4431,"primaryCompletion":4409,"completion":4409,"start":4410,"enrollment":4411,"conditions":4432,"interventions":4433},[90],[4413],[4397,4415],{"trials":4435,"activeCount":100},[],{"trials":4437,"activeCount":100},[],{"trials":4439,"activeCount":100},[],{"intervention":4441,"totalTrials":379,"cells":4442},"OPS-2071",{"EARLY_PHASE1":4443,"PHASE1":4445,"PHASE2":4447,"PHASE3":4458,"PHASE4":4460,"NA":4462},{"trials":4444,"activeCount":100},[],{"trials":4446,"activeCount":100},[],{"trials":4448,"activeCount":100},[4449],{"nctId":4450,"briefTitle":4451,"status":236,"phases":4452,"primaryCompletion":4453,"completion":4453,"start":4454,"enrollment":240,"conditions":4455,"interventions":4457},"NCT03850509","Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation",[90],"2020-05-22","2020-02-25",[4456],"Crohn's Disease",[4441],{"trials":4459,"activeCount":100},[],{"trials":4461,"activeCount":100},[],{"trials":4463,"activeCount":100},[],{"intervention":4465,"totalTrials":379,"cells":4466},"OPDC-34712",{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4482,"PHASE4":4484,"NA":4486},{"trials":4468,"activeCount":100},[],{"trials":4470,"activeCount":100},[],{"trials":4472,"activeCount":100},[4473],{"nctId":4474,"briefTitle":4475,"status":108,"phases":4476,"primaryCompletion":4477,"completion":4477,"start":4478,"enrollment":2719,"conditions":4479,"interventions":4480},"NCT01074294","Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit\u002FHyperactivity Disorder",[90],"2011-06-20","2010-03-16",[2340],[4465,4481],"Stimulant Therapy",{"trials":4483,"activeCount":100},[],{"trials":4485,"activeCount":100},[],{"trials":4487,"activeCount":100},[],{"intervention":4481,"totalTrials":379,"cells":4489},{"EARLY_PHASE1":4490,"PHASE1":4492,"PHASE2":4494,"PHASE3":4500,"PHASE4":4502,"NA":4504},{"trials":4491,"activeCount":100},[],{"trials":4493,"activeCount":100},[],{"trials":4495,"activeCount":100},[4496],{"nctId":4474,"briefTitle":4475,"status":108,"phases":4497,"primaryCompletion":4477,"completion":4477,"start":4478,"enrollment":2719,"conditions":4498,"interventions":4499},[90],[2340],[4465,4481],{"trials":4501,"activeCount":100},[],{"trials":4503,"activeCount":100},[],{"trials":4505,"activeCount":100},[],{"intervention":2078,"totalTrials":96,"cells":4507},{"EARLY_PHASE1":4508,"PHASE1":4510,"PHASE2":4537,"PHASE3":4539,"PHASE4":4541,"NA":4543},{"trials":4509,"activeCount":100},[],{"trials":4511,"activeCount":100},[4512,4525,4529,4533],{"nctId":4513,"briefTitle":4514,"status":108,"phases":4515,"primaryCompletion":4516,"completion":4516,"start":4517,"enrollment":450,"conditions":4518,"interventions":4519},"NCT01787747","Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers",[89],"2013-02-01","2012-10-01",[2076],[4520,4521,4522,4523,4524,2078],"AVP-786 Dose 1","AVP-786 Dose 2","AVP-786 Dose 1\u002FQ Dose 1","AVP-786 Dose 1\u002FQ Dose 2","AVP-786 Dose 2\u002FQ Dose 2",{"nctId":2070,"briefTitle":2071,"status":108,"phases":4526,"primaryCompletion":2073,"completion":2073,"start":2074,"enrollment":2063,"conditions":4527,"interventions":4528},[89],[2076],[2050,2078],{"nctId":2080,"briefTitle":2081,"status":108,"phases":4530,"primaryCompletion":2083,"completion":2083,"start":2084,"enrollment":785,"conditions":4531,"interventions":4532},[89],[2076],[2078,2050,789],{"nctId":2088,"briefTitle":2089,"status":108,"phases":4534,"primaryCompletion":2091,"completion":2084,"start":2092,"enrollment":967,"conditions":4535,"interventions":4536},[89],[2094],[2050,2078],{"trials":4538,"activeCount":100},[],{"trials":4540,"activeCount":100},[],{"trials":4542,"activeCount":100},[],{"trials":4544,"activeCount":100},[],{"intervention":426,"totalTrials":146,"cells":4546},{"EARLY_PHASE1":4547,"PHASE1":4549,"PHASE2":4559,"PHASE3":4561,"PHASE4":4563,"NA":4565},{"trials":4548,"activeCount":100},[],{"trials":4550,"activeCount":100},[4551,4555],{"nctId":418,"briefTitle":419,"status":108,"phases":4552,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":4553,"interventions":4554},[89],[15],[56,426],{"nctId":428,"briefTitle":429,"status":108,"phases":4556,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":4557,"interventions":4558},[89],[15],[56,426],{"trials":4560,"activeCount":100},[],{"trials":4562,"activeCount":100},[],{"trials":4564,"activeCount":100},[],{"trials":4566,"activeCount":100},[],{"intervention":4568,"totalTrials":146,"cells":4569},"SEP-380135",{"EARLY_PHASE1":4570,"PHASE1":4572,"PHASE2":4591,"PHASE3":4593,"PHASE4":4595,"NA":4597},{"trials":4571,"activeCount":100},[],{"trials":4573,"activeCount":100},[4574,4583],{"nctId":4575,"briefTitle":4576,"status":108,"phases":4577,"primaryCompletion":4578,"completion":4578,"start":4579,"enrollment":24,"conditions":4580,"interventions":4581},"NCT07305779","A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women",[89],"2025-05-03","2025-03-07",[15],[4568,4582],"Quinidine Gluconate",{"nctId":4584,"briefTitle":4585,"status":108,"phases":4586,"primaryCompletion":4587,"completion":4587,"start":4588,"enrollment":1555,"conditions":4589,"interventions":4590},"NCT07549581","A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode",[89],"2025-09-12","2024-11-07",[15,35,21],[4568],{"trials":4592,"activeCount":100},[],{"trials":4594,"activeCount":100},[],{"trials":4596,"activeCount":100},[],{"trials":4598,"activeCount":100},[],{"intervention":789,"totalTrials":146,"cells":4600},{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4613,"PHASE3":4615,"PHASE4":4617,"NA":4619},{"trials":4602,"activeCount":100},[],{"trials":4604,"activeCount":100},[4605,4609],{"nctId":2080,"briefTitle":2081,"status":108,"phases":4606,"primaryCompletion":2083,"completion":2083,"start":2084,"enrollment":785,"conditions":4607,"interventions":4608},[89],[2076],[2078,2050,789],{"nctId":779,"briefTitle":780,"status":108,"phases":4610,"primaryCompletion":782,"completion":783,"start":784,"enrollment":785,"conditions":4611,"interventions":4612},[89],[32],[788,789,755],{"trials":4614,"activeCount":100},[],{"trials":4616,"activeCount":100},[],{"trials":4618,"activeCount":100},[],{"trials":4620,"activeCount":100},[],{"intervention":2067,"totalTrials":379,"cells":4622},{"EARLY_PHASE1":4623,"PHASE1":4625,"PHASE2":4631,"PHASE3":4633,"PHASE4":4635,"NA":4637},{"trials":4624,"activeCount":100},[],{"trials":4626,"activeCount":100},[4627],{"nctId":2058,"briefTitle":2059,"status":108,"phases":4628,"primaryCompletion":396,"completion":2061,"start":2062,"enrollment":2063,"conditions":4629,"interventions":4630},[89],[2065],[2050,2067,2068],{"trials":4632,"activeCount":100},[],{"trials":4634,"activeCount":100},[],{"trials":4636,"activeCount":100},[],{"trials":4638,"activeCount":100},[],{"intervention":3688,"totalTrials":379,"cells":4640},{"EARLY_PHASE1":4641,"PHASE1":4643,"PHASE2":4649,"PHASE3":4651,"PHASE4":4653,"NA":4655},{"trials":4642,"activeCount":100},[],{"trials":4644,"activeCount":100},[4645],{"nctId":3679,"briefTitle":3680,"status":108,"phases":4646,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":1587,"conditions":4647,"interventions":4648},[89],[3663,3686],[3688,3689,3690,3691,3692,3619],{"trials":4650,"activeCount":100},[],{"trials":4652,"activeCount":100},[],{"trials":4654,"activeCount":100},[],{"trials":4656,"activeCount":100},[],{"intervention":3689,"totalTrials":379,"cells":4658},{"EARLY_PHASE1":4659,"PHASE1":4661,"PHASE2":4667,"PHASE3":4669,"PHASE4":4671,"NA":4673},{"trials":4660,"activeCount":100},[],{"trials":4662,"activeCount":100},[4663],{"nctId":3679,"briefTitle":3680,"status":108,"phases":4664,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":1587,"conditions":4665,"interventions":4666},[89],[3663,3686],[3688,3689,3690,3691,3692,3619],{"trials":4668,"activeCount":100},[],{"trials":4670,"activeCount":100},[],{"trials":4672,"activeCount":100},[],{"trials":4674,"activeCount":100},[],{"intervention":3690,"totalTrials":379,"cells":4676},{"EARLY_PHASE1":4677,"PHASE1":4679,"PHASE2":4685,"PHASE3":4687,"PHASE4":4689,"NA":4691},{"trials":4678,"activeCount":100},[],{"trials":4680,"activeCount":100},[4681],{"nctId":3679,"briefTitle":3680,"status":108,"phases":4682,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":1587,"conditions":4683,"interventions":4684},[89],[3663,3686],[3688,3689,3690,3691,3692,3619],{"trials":4686,"activeCount":100},[],{"trials":4688,"activeCount":100},[],{"trials":4690,"activeCount":100},[],{"trials":4692,"activeCount":100},[],{"intervention":3691,"totalTrials":379,"cells":4694},{"EARLY_PHASE1":4695,"PHASE1":4697,"PHASE2":4703,"PHASE3":4705,"PHASE4":4707,"NA":4709},{"trials":4696,"activeCount":100},[],{"trials":4698,"activeCount":100},[4699],{"nctId":3679,"briefTitle":3680,"status":108,"phases":4700,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":1587,"conditions":4701,"interventions":4702},[89],[3663,3686],[3688,3689,3690,3691,3692,3619],{"trials":4704,"activeCount":100},[],{"trials":4706,"activeCount":100},[],{"trials":4708,"activeCount":100},[],{"trials":4710,"activeCount":100},[],{"intervention":3692,"totalTrials":379,"cells":4712},{"EARLY_PHASE1":4713,"PHASE1":4715,"PHASE2":4721,"PHASE3":4723,"PHASE4":4725,"NA":4727},{"trials":4714,"activeCount":100},[],{"trials":4716,"activeCount":100},[4717],{"nctId":3679,"briefTitle":3680,"status":108,"phases":4718,"primaryCompletion":3682,"completion":3683,"start":3684,"enrollment":1587,"conditions":4719,"interventions":4720},[89],[3663,3686],[3688,3689,3690,3691,3692,3619],{"trials":4722,"activeCount":100},[],{"trials":4724,"activeCount":100},[],{"trials":4726,"activeCount":100},[],{"trials":4728,"activeCount":100},[],{"intervention":400,"totalTrials":379,"cells":4730},{"EARLY_PHASE1":4731,"PHASE1":4733,"PHASE2":4739,"PHASE3":4741,"PHASE4":4743,"NA":4745},{"trials":4732,"activeCount":100},[],{"trials":4734,"activeCount":100},[4735],{"nctId":392,"briefTitle":393,"status":108,"phases":4736,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":4737,"interventions":4738},[89],[15],[56,400],{"trials":4740,"activeCount":100},[],{"trials":4742,"activeCount":100},[],{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[],{"intervention":2322,"totalTrials":379,"cells":4748},{"EARLY_PHASE1":4749,"PHASE1":4751,"PHASE2":4757,"PHASE3":4759,"PHASE4":4761,"NA":4763},{"trials":4750,"activeCount":100},[],{"trials":4752,"activeCount":100},[4753],{"nctId":2314,"briefTitle":2315,"status":108,"phases":4754,"primaryCompletion":2317,"completion":2318,"start":2319,"enrollment":208,"conditions":4755,"interventions":4756},[89],[1544],[2299,2322,2323],{"trials":4758,"activeCount":100},[],{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[],{"trials":4764,"activeCount":100},[],{"intervention":2323,"totalTrials":379,"cells":4766},{"EARLY_PHASE1":4767,"PHASE1":4769,"PHASE2":4775,"PHASE3":4777,"PHASE4":4779,"NA":4781},{"trials":4768,"activeCount":100},[],{"trials":4770,"activeCount":100},[4771],{"nctId":2314,"briefTitle":2315,"status":108,"phases":4772,"primaryCompletion":2317,"completion":2318,"start":2319,"enrollment":208,"conditions":4773,"interventions":4774},[89],[1544],[2299,2322,2323],{"trials":4776,"activeCount":100},[],{"trials":4778,"activeCount":100},[],{"trials":4780,"activeCount":100},[],{"trials":4782,"activeCount":100},[],{"intervention":4784,"totalTrials":379,"cells":4785},"[14C]-JNT-517",{"EARLY_PHASE1":4786,"PHASE1":4788,"PHASE2":4799,"PHASE3":4801,"PHASE4":4803,"NA":4805},{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":100},[4790],{"nctId":4791,"briefTitle":4792,"status":108,"phases":4793,"primaryCompletion":4794,"completion":4795,"start":4796,"enrollment":30,"conditions":4797,"interventions":4798},"NCT07573449","How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants",[89],"2025-01-22","2025-02-27","2024-01-22",[32],[4784],{"trials":4800,"activeCount":100},[],{"trials":4802,"activeCount":100},[],{"trials":4804,"activeCount":100},[],{"trials":4806,"activeCount":100},[],{"intervention":4808,"totalTrials":379,"cells":4809},"EB-1020 400 mg",{"EARLY_PHASE1":4810,"PHASE1":4812,"PHASE2":4826,"PHASE3":4828,"PHASE4":4830,"NA":4832},{"trials":4811,"activeCount":100},[],{"trials":4813,"activeCount":100},[4814],{"nctId":4815,"briefTitle":4816,"status":108,"phases":4817,"primaryCompletion":4818,"completion":4818,"start":2092,"enrollment":4819,"conditions":4820,"interventions":4822},"NCT02144415","A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users",[89],"2014-07-01",80,[32,4821],"Drug Users",[4808,4823,4824,4825],"EB-1020 800 mg","lisdexamfetamine 150 mg","d-amphetamine 40 mg",{"trials":4827,"activeCount":100},[],{"trials":4829,"activeCount":100},[],{"trials":4831,"activeCount":100},[],{"trials":4833,"activeCount":100},[],{"intervention":4823,"totalTrials":379,"cells":4835},{"EARLY_PHASE1":4836,"PHASE1":4838,"PHASE2":4844,"PHASE3":4846,"PHASE4":4848,"NA":4850},{"trials":4837,"activeCount":100},[],{"trials":4839,"activeCount":100},[4840],{"nctId":4815,"briefTitle":4816,"status":108,"phases":4841,"primaryCompletion":4818,"completion":4818,"start":2092,"enrollment":4819,"conditions":4842,"interventions":4843},[89],[32,4821],[4808,4823,4824,4825],{"trials":4845,"activeCount":100},[],{"trials":4847,"activeCount":100},[],{"trials":4849,"activeCount":100},[],{"trials":4851,"activeCount":100},[],{"intervention":4824,"totalTrials":379,"cells":4853},{"EARLY_PHASE1":4854,"PHASE1":4856,"PHASE2":4862,"PHASE3":4864,"PHASE4":4866,"NA":4868},{"trials":4855,"activeCount":100},[],{"trials":4857,"activeCount":100},[4858],{"nctId":4815,"briefTitle":4816,"status":108,"phases":4859,"primaryCompletion":4818,"completion":4818,"start":2092,"enrollment":4819,"conditions":4860,"interventions":4861},[89],[32,4821],[4808,4823,4824,4825],{"trials":4863,"activeCount":100},[],{"trials":4865,"activeCount":100},[],{"trials":4867,"activeCount":100},[],{"trials":4869,"activeCount":100},[],{"intervention":4825,"totalTrials":379,"cells":4871},{"EARLY_PHASE1":4872,"PHASE1":4874,"PHASE2":4880,"PHASE3":4882,"PHASE4":4884,"NA":4886},{"trials":4873,"activeCount":100},[],{"trials":4875,"activeCount":100},[4876],{"nctId":4815,"briefTitle":4816,"status":108,"phases":4877,"primaryCompletion":4818,"completion":4818,"start":2092,"enrollment":4819,"conditions":4878,"interventions":4879},[89],[32,4821],[4808,4823,4824,4825],{"trials":4881,"activeCount":100},[],{"trials":4883,"activeCount":100},[],{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[],{"intervention":4889,"totalTrials":379,"cells":4890},"Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.",{"EARLY_PHASE1":4891,"PHASE1":4893,"PHASE2":4901,"PHASE3":4903,"PHASE4":4905,"NA":4907},{"trials":4892,"activeCount":100},[],{"trials":4894,"activeCount":100},[4895],{"nctId":4896,"briefTitle":4897,"status":108,"phases":4898,"primaryCompletion":1222,"completion":1222,"start":1209,"enrollment":1772,"conditions":4899,"interventions":4900},"NCT00362271","Aripiprazole and Effexor XR Drug Interaction Study",[89],[2076],[4889],{"trials":4902,"activeCount":100},[],{"trials":4904,"activeCount":100},[],{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[],{"intervention":4910,"totalTrials":379,"cells":4911},"Brexpiprazole, OPDC-34712",{"EARLY_PHASE1":4912,"PHASE1":4914,"PHASE2":4924,"PHASE3":4926,"PHASE4":4928,"NA":4930},{"trials":4913,"activeCount":100},[],{"trials":4915,"activeCount":100},[4916],{"nctId":4917,"briefTitle":4918,"status":236,"phases":4919,"primaryCompletion":4920,"completion":4920,"start":4921,"enrollment":153,"conditions":4922,"interventions":4923},"NCT02968121","Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia",[89],"2017-12-14","2017-01",[15],[4910],{"trials":4925,"activeCount":100},[],{"trials":4927,"activeCount":100},[],{"trials":4929,"activeCount":100},[],{"trials":4931,"activeCount":100},[],{"intervention":4933,"totalTrials":379,"cells":4934},"CAN10",{"EARLY_PHASE1":4935,"PHASE1":4937,"PHASE2":4949,"PHASE3":4951,"PHASE4":4953,"NA":4955},{"trials":4936,"activeCount":100},[],{"trials":4938,"activeCount":100},[4939],{"nctId":4940,"briefTitle":4941,"status":108,"phases":4942,"primaryCompletion":4943,"completion":4943,"start":4944,"enrollment":4819,"conditions":4945,"interventions":4947},"NCT06143371","A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.",[89],"2025-11-10","2023-08-21",[2076,4946],"Plaque Psoriasis",[4933,4948],"CAN10 - Placebo",{"trials":4950,"activeCount":100},[],{"trials":4952,"activeCount":100},[],{"trials":4954,"activeCount":100},[],{"trials":4956,"activeCount":100},[],{"intervention":4948,"totalTrials":379,"cells":4958},{"EARLY_PHASE1":4959,"PHASE1":4961,"PHASE2":4967,"PHASE3":4969,"PHASE4":4971,"NA":4973},{"trials":4960,"activeCount":100},[],{"trials":4962,"activeCount":100},[4963],{"nctId":4940,"briefTitle":4941,"status":108,"phases":4964,"primaryCompletion":4943,"completion":4943,"start":4944,"enrollment":4819,"conditions":4965,"interventions":4966},[89],[2076,4946],[4933,4948],{"trials":4968,"activeCount":100},[],{"trials":4970,"activeCount":100},[],{"trials":4972,"activeCount":100},[],{"trials":4974,"activeCount":100},[],{"intervention":4520,"totalTrials":379,"cells":4976},{"EARLY_PHASE1":4977,"PHASE1":4979,"PHASE2":4985,"PHASE3":4987,"PHASE4":4989,"NA":4991},{"trials":4978,"activeCount":100},[],{"trials":4980,"activeCount":100},[4981],{"nctId":4513,"briefTitle":4514,"status":108,"phases":4982,"primaryCompletion":4516,"completion":4516,"start":4517,"enrollment":450,"conditions":4983,"interventions":4984},[89],[2076],[4520,4521,4522,4523,4524,2078],{"trials":4986,"activeCount":100},[],{"trials":4988,"activeCount":100},[],{"trials":4990,"activeCount":100},[],{"trials":4992,"activeCount":100},[],{"intervention":4521,"totalTrials":379,"cells":4994},{"EARLY_PHASE1":4995,"PHASE1":4997,"PHASE2":5003,"PHASE3":5005,"PHASE4":5007,"NA":5009},{"trials":4996,"activeCount":100},[],{"trials":4998,"activeCount":100},[4999],{"nctId":4513,"briefTitle":4514,"status":108,"phases":5000,"primaryCompletion":4516,"completion":4516,"start":4517,"enrollment":450,"conditions":5001,"interventions":5002},[89],[2076],[4520,4521,4522,4523,4524,2078],{"trials":5004,"activeCount":100},[],{"trials":5006,"activeCount":100},[],{"trials":5008,"activeCount":100},[],{"trials":5010,"activeCount":100},[],{"intervention":4522,"totalTrials":379,"cells":5012},{"EARLY_PHASE1":5013,"PHASE1":5015,"PHASE2":5021,"PHASE3":5023,"PHASE4":5025,"NA":5027},{"trials":5014,"activeCount":100},[],{"trials":5016,"activeCount":100},[5017],{"nctId":4513,"briefTitle":4514,"status":108,"phases":5018,"primaryCompletion":4516,"completion":4516,"start":4517,"enrollment":450,"conditions":5019,"interventions":5020},[89],[2076],[4520,4521,4522,4523,4524,2078],{"trials":5022,"activeCount":100},[],{"trials":5024,"activeCount":100},[],{"trials":5026,"activeCount":100},[],{"trials":5028,"activeCount":100},[],{"intervention":4523,"totalTrials":379,"cells":5030},{"EARLY_PHASE1":5031,"PHASE1":5033,"PHASE2":5039,"PHASE3":5041,"PHASE4":5043,"NA":5045},{"trials":5032,"activeCount":100},[],{"trials":5034,"activeCount":100},[5035],{"nctId":4513,"briefTitle":4514,"status":108,"phases":5036,"primaryCompletion":4516,"completion":4516,"start":4517,"enrollment":450,"conditions":5037,"interventions":5038},[89],[2076],[4520,4521,4522,4523,4524,2078],{"trials":5040,"activeCount":100},[],{"trials":5042,"activeCount":100},[],{"trials":5044,"activeCount":100},[],{"trials":5046,"activeCount":100},[],{"intervention":4524,"totalTrials":379,"cells":5048},{"EARLY_PHASE1":5049,"PHASE1":5051,"PHASE2":5057,"PHASE3":5059,"PHASE4":5061,"NA":5063},{"trials":5050,"activeCount":100},[],{"trials":5052,"activeCount":100},[5053],{"nctId":4513,"briefTitle":4514,"status":108,"phases":5054,"primaryCompletion":4516,"completion":4516,"start":4517,"enrollment":450,"conditions":5055,"interventions":5056},[89],[2076],[4520,4521,4522,4523,4524,2078],{"trials":5058,"activeCount":100},[],{"trials":5060,"activeCount":100},[],{"trials":5062,"activeCount":100},[],{"trials":5064,"activeCount":100},[],{"intervention":5066,"totalTrials":379,"cells":5067},"Propranolol",{"EARLY_PHASE1":5068,"PHASE1":5070,"PHASE2":5083,"PHASE3":5085,"PHASE4":5087,"NA":5089},{"trials":5069,"activeCount":100},[],{"trials":5071,"activeCount":100},[5072],{"nctId":5073,"briefTitle":5074,"status":236,"phases":5075,"primaryCompletion":5076,"completion":5076,"start":5077,"enrollment":5078,"conditions":5079,"interventions":5081},"NCT05189977","A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole\u002FSertraline",[89],"2023-08-03","2022-09-07",34,[5080],"Post-traumatic Stress Disorder (PTSD)",[5066,5082],"Prazosin",{"trials":5084,"activeCount":100},[],{"trials":5086,"activeCount":100},[],{"trials":5088,"activeCount":100},[],{"trials":5090,"activeCount":100},[],{"intervention":5082,"totalTrials":379,"cells":5092},{"EARLY_PHASE1":5093,"PHASE1":5095,"PHASE2":5101,"PHASE3":5103,"PHASE4":5105,"NA":5107},{"trials":5094,"activeCount":100},[],{"trials":5096,"activeCount":100},[5097],{"nctId":5073,"briefTitle":5074,"status":236,"phases":5098,"primaryCompletion":5076,"completion":5076,"start":5077,"enrollment":5078,"conditions":5099,"interventions":5100},[89],[5080],[5066,5082],{"trials":5102,"activeCount":100},[],{"trials":5104,"activeCount":100},[],{"trials":5106,"activeCount":100},[],{"trials":5108,"activeCount":100},[],{"intervention":5110,"totalTrials":379,"cells":5111},"OPB-111077",{"EARLY_PHASE1":5112,"PHASE1":5114,"PHASE2":5125,"PHASE3":5127,"PHASE4":5129,"NA":5131},{"trials":5113,"activeCount":100},[],{"trials":5115,"activeCount":100},[5116],{"nctId":5117,"briefTitle":5118,"status":108,"phases":5119,"primaryCompletion":5120,"completion":5120,"start":5121,"enrollment":2113,"conditions":5122,"interventions":5124},"NCT01711034","A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer",[89],"2015-12","2012-06",[5123],"Solid Tumors",[5110],{"trials":5126,"activeCount":100},[],{"trials":5128,"activeCount":100},[],{"trials":5130,"activeCount":100},[],{"trials":5132,"activeCount":100},[],{"intervention":3730,"totalTrials":379,"cells":5134},{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5143,"PHASE3":5145,"PHASE4":5147,"NA":5149},{"trials":5136,"activeCount":100},[],{"trials":5138,"activeCount":100},[5139],{"nctId":3721,"briefTitle":3722,"status":108,"phases":5140,"primaryCompletion":3724,"completion":3724,"start":3725,"enrollment":3726,"conditions":5141,"interventions":5142},[89],[3728],[3730,3714,3730],{"trials":5144,"activeCount":100},[],{"trials":5146,"activeCount":100},[],{"trials":5148,"activeCount":100},[],{"trials":5150,"activeCount":100},[],{"intervention":5152,"totalTrials":379,"cells":5153},"EB-1020 IR",{"EARLY_PHASE1":5154,"PHASE1":5156,"PHASE2":5170,"PHASE3":5172,"PHASE4":5174,"NA":5176},{"trials":5155,"activeCount":100},[],{"trials":5157,"activeCount":100},[5158],{"nctId":5159,"briefTitle":5160,"status":108,"phases":5161,"primaryCompletion":5162,"completion":5162,"start":4516,"enrollment":5163,"conditions":5164,"interventions":5166},"NCT01744808","A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020",[89],"2014-02-01",54,[5165],"Normal, Healthy Volunteers",[5152,5167,5168,5169],"EB-1020 SR1","EB-1020 SR2","EB-1020 SR3",{"trials":5171,"activeCount":100},[],{"trials":5173,"activeCount":100},[],{"trials":5175,"activeCount":100},[],{"trials":5177,"activeCount":100},[],{"intervention":5167,"totalTrials":379,"cells":5179},{"EARLY_PHASE1":5180,"PHASE1":5182,"PHASE2":5188,"PHASE3":5190,"PHASE4":5192,"NA":5194},{"trials":5181,"activeCount":100},[],{"trials":5183,"activeCount":100},[5184],{"nctId":5159,"briefTitle":5160,"status":108,"phases":5185,"primaryCompletion":5162,"completion":5162,"start":4516,"enrollment":5163,"conditions":5186,"interventions":5187},[89],[5165],[5152,5167,5168,5169],{"trials":5189,"activeCount":100},[],{"trials":5191,"activeCount":100},[],{"trials":5193,"activeCount":100},[],{"trials":5195,"activeCount":100},[],{"intervention":5168,"totalTrials":379,"cells":5197},{"EARLY_PHASE1":5198,"PHASE1":5200,"PHASE2":5206,"PHASE3":5208,"PHASE4":5210,"NA":5212},{"trials":5199,"activeCount":100},[],{"trials":5201,"activeCount":100},[5202],{"nctId":5159,"briefTitle":5160,"status":108,"phases":5203,"primaryCompletion":5162,"completion":5162,"start":4516,"enrollment":5163,"conditions":5204,"interventions":5205},[89],[5165],[5152,5167,5168,5169],{"trials":5207,"activeCount":100},[],{"trials":5209,"activeCount":100},[],{"trials":5211,"activeCount":100},[],{"trials":5213,"activeCount":100},[],{"intervention":5169,"totalTrials":379,"cells":5215},{"EARLY_PHASE1":5216,"PHASE1":5218,"PHASE2":5224,"PHASE3":5226,"PHASE4":5228,"NA":5230},{"trials":5217,"activeCount":100},[],{"trials":5219,"activeCount":100},[5220],{"nctId":5159,"briefTitle":5160,"status":108,"phases":5221,"primaryCompletion":5162,"completion":5162,"start":4516,"enrollment":5163,"conditions":5222,"interventions":5223},[89],[5165],[5152,5167,5168,5169],{"trials":5225,"activeCount":100},[],{"trials":5227,"activeCount":100},[],{"trials":5229,"activeCount":100},[],{"trials":5231,"activeCount":100},[],{"intervention":5233,"totalTrials":379,"cells":5234},"Aripiprazole, OPC-14597",{"EARLY_PHASE1":5235,"PHASE1":5237,"PHASE2":5246,"PHASE3":5248,"PHASE4":5250,"NA":5252},{"trials":5236,"activeCount":100},[],{"trials":5238,"activeCount":100},[5239],{"nctId":5240,"briefTitle":5241,"status":108,"phases":5242,"primaryCompletion":396,"completion":2061,"start":3867,"enrollment":5243,"conditions":5244,"interventions":5245},"NCT01909466","Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia",[89],141,[15,29,1046],[5233],{"trials":5247,"activeCount":100},[],{"trials":5249,"activeCount":100},[],{"trials":5251,"activeCount":100},[],{"trials":5253,"activeCount":100},[],{"intervention":2517,"totalTrials":379,"cells":5255},{"EARLY_PHASE1":5256,"PHASE1":5258,"PHASE2":5264,"PHASE3":5266,"PHASE4":5268,"NA":5270},{"trials":5257,"activeCount":100},[],{"trials":5259,"activeCount":100},[5260],{"nctId":2510,"briefTitle":2511,"status":108,"phases":5261,"primaryCompletion":2513,"completion":2513,"start":2514,"enrollment":967,"conditions":5262,"interventions":5263},[89],[32],[2503,2517],{"trials":5265,"activeCount":100},[],{"trials":5267,"activeCount":100},[],{"trials":5269,"activeCount":100},[],{"trials":5271,"activeCount":100},[],{"intervention":2217,"totalTrials":379,"cells":5273},{"EARLY_PHASE1":5274,"PHASE1":5276,"PHASE2":5282,"PHASE3":5284,"PHASE4":5286,"NA":5288},{"trials":5275,"activeCount":100},[],{"trials":5277,"activeCount":100},[5278],{"nctId":2210,"briefTitle":2211,"status":108,"phases":5279,"primaryCompletion":2213,"completion":2214,"start":1243,"enrollment":1126,"conditions":5280,"interventions":5281},[89],[15,1214],[1039,2217,1039],{"trials":5283,"activeCount":100},[],{"trials":5285,"activeCount":100},[],{"trials":5287,"activeCount":100},[],{"trials":5289,"activeCount":100},[],{"intervention":5291,"totalTrials":379,"cells":5292},"OPC-108459",{"EARLY_PHASE1":5293,"PHASE1":5295,"PHASE2":5307,"PHASE3":5309,"PHASE4":5311,"NA":5313},{"trials":5294,"activeCount":100},[],{"trials":5296,"activeCount":100},[5297],{"nctId":5298,"briefTitle":5299,"status":236,"phases":5300,"primaryCompletion":5301,"completion":5301,"start":215,"enrollment":208,"conditions":5302,"interventions":5306},"NCT01483183","Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation",[89],"2015-10",[5303,5304,5305],"Atrial Fibrillation","Paroxysmal Atrial Fibrillation","Persistent Atrial Fibrillation",[5291],{"trials":5308,"activeCount":100},[],{"trials":5310,"activeCount":100},[],{"trials":5312,"activeCount":100},[],{"trials":5314,"activeCount":100},[],{"intervention":4582,"totalTrials":379,"cells":5316},{"EARLY_PHASE1":5317,"PHASE1":5319,"PHASE2":5325,"PHASE3":5327,"PHASE4":5329,"NA":5331},{"trials":5318,"activeCount":100},[],{"trials":5320,"activeCount":100},[5321],{"nctId":4575,"briefTitle":4576,"status":108,"phases":5322,"primaryCompletion":4578,"completion":4578,"start":4579,"enrollment":24,"conditions":5323,"interventions":5324},[89],[15],[4568,4582],{"trials":5326,"activeCount":100},[],{"trials":5328,"activeCount":100},[],{"trials":5330,"activeCount":100},[],{"trials":5332,"activeCount":100},[],{"intervention":5334,"totalTrials":379,"cells":5335},"Seroquel IR 300mg",{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5353,"PHASE3":5355,"PHASE4":5357,"NA":5359},{"trials":5337,"activeCount":100},[],{"trials":5339,"activeCount":100},[5340],{"nctId":5341,"briefTitle":5342,"status":108,"phases":5343,"primaryCompletion":1681,"completion":5344,"start":5345,"enrollment":5346,"conditions":5347,"interventions":5348},"NCT03872596","Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder",[89],"2019-11-27","2019-03-27",58,[21,15],[5334,5349,5350,5351,5352],"Seroquel IR 25mg","Quetiapine Formulation A 300mg","Quetiapine Formulation B 300mg","Quetiapine Formulation 25mg",{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[],{"trials":5358,"activeCount":100},[],{"trials":5360,"activeCount":100},[],{"intervention":5349,"totalTrials":379,"cells":5362},{"EARLY_PHASE1":5363,"PHASE1":5365,"PHASE2":5371,"PHASE3":5373,"PHASE4":5375,"NA":5377},{"trials":5364,"activeCount":100},[],{"trials":5366,"activeCount":100},[5367],{"nctId":5341,"briefTitle":5342,"status":108,"phases":5368,"primaryCompletion":1681,"completion":5344,"start":5345,"enrollment":5346,"conditions":5369,"interventions":5370},[89],[21,15],[5334,5349,5350,5351,5352],{"trials":5372,"activeCount":100},[],{"trials":5374,"activeCount":100},[],{"trials":5376,"activeCount":100},[],{"trials":5378,"activeCount":100},[],{"intervention":5350,"totalTrials":379,"cells":5380},{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5389,"PHASE3":5391,"PHASE4":5393,"NA":5395},{"trials":5382,"activeCount":100},[],{"trials":5384,"activeCount":100},[5385],{"nctId":5341,"briefTitle":5342,"status":108,"phases":5386,"primaryCompletion":1681,"completion":5344,"start":5345,"enrollment":5346,"conditions":5387,"interventions":5388},[89],[21,15],[5334,5349,5350,5351,5352],{"trials":5390,"activeCount":100},[],{"trials":5392,"activeCount":100},[],{"trials":5394,"activeCount":100},[],{"trials":5396,"activeCount":100},[],{"intervention":5351,"totalTrials":379,"cells":5398},{"EARLY_PHASE1":5399,"PHASE1":5401,"PHASE2":5407,"PHASE3":5409,"PHASE4":5411,"NA":5413},{"trials":5400,"activeCount":100},[],{"trials":5402,"activeCount":100},[5403],{"nctId":5341,"briefTitle":5342,"status":108,"phases":5404,"primaryCompletion":1681,"completion":5344,"start":5345,"enrollment":5346,"conditions":5405,"interventions":5406},[89],[21,15],[5334,5349,5350,5351,5352],{"trials":5408,"activeCount":100},[],{"trials":5410,"activeCount":100},[],{"trials":5412,"activeCount":100},[],{"trials":5414,"activeCount":100},[],{"intervention":5352,"totalTrials":379,"cells":5416},{"EARLY_PHASE1":5417,"PHASE1":5419,"PHASE2":5425,"PHASE3":5427,"PHASE4":5429,"NA":5431},{"trials":5418,"activeCount":100},[],{"trials":5420,"activeCount":100},[5421],{"nctId":5341,"briefTitle":5342,"status":108,"phases":5422,"primaryCompletion":1681,"completion":5344,"start":5345,"enrollment":5346,"conditions":5423,"interventions":5424},[89],[21,15],[5334,5349,5350,5351,5352],{"trials":5426,"activeCount":100},[],{"trials":5428,"activeCount":100},[],{"trials":5430,"activeCount":100},[],{"trials":5432,"activeCount":100},[],{"intervention":5434,"totalTrials":379,"cells":5435},"[14C]-OPC-167832",{"EARLY_PHASE1":5436,"PHASE1":5438,"PHASE2":5448,"PHASE3":5450,"PHASE4":5452,"NA":5454},{"trials":5437,"activeCount":100},[],{"trials":5439,"activeCount":100},[5440],{"nctId":5441,"briefTitle":5442,"status":108,"phases":5443,"primaryCompletion":5444,"completion":5444,"start":5445,"enrollment":30,"conditions":5446,"interventions":5447},"NCT07314320","A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men",[89],"2023-12-27","2023-11-20",[32],[5434],{"trials":5449,"activeCount":100},[],{"trials":5451,"activeCount":100},[],{"trials":5453,"activeCount":100},[],{"trials":5455,"activeCount":100},[],{"intervention":5457,"totalTrials":379,"cells":5458},"OPC-214870",{"EARLY_PHASE1":5459,"PHASE1":5461,"PHASE2":5474,"PHASE3":5476,"PHASE4":5478,"NA":5480},{"trials":5460,"activeCount":100},[],{"trials":5462,"activeCount":100},[5463],{"nctId":5464,"briefTitle":5465,"status":108,"phases":5466,"primaryCompletion":5467,"completion":5468,"start":5469,"enrollment":5470,"conditions":5471,"interventions":5473},"NCT04241965","A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870",[89],"2021-10-11","2021-10-28","2020-02-18",16,[5472],"Epilepsy",[5457],{"trials":5475,"activeCount":100},[],{"trials":5477,"activeCount":100},[],{"trials":5479,"activeCount":100},[],{"trials":5481,"activeCount":100},[],{"intervention":5483,"totalTrials":379,"cells":5484},"VIS649",{"EARLY_PHASE1":5485,"PHASE1":5487,"PHASE2":5499,"PHASE3":5501,"PHASE4":5503,"NA":5505},{"trials":5486,"activeCount":100},[],{"trials":5488,"activeCount":100},[5489],{"nctId":5490,"briefTitle":5491,"status":108,"phases":5492,"primaryCompletion":5493,"completion":5493,"start":5494,"enrollment":5495,"conditions":5496,"interventions":5498},"NCT03719443","First in Human Study to Assess Safety of VIS649 in Healthy Subjects",[89],"2019-08-10","2018-10-09",51,[582,5497,723],"IgAN - IgA Nephropathy",[5483],{"trials":5500,"activeCount":100},[],{"trials":5502,"activeCount":100},[],{"trials":5504,"activeCount":100},[],{"trials":5506,"activeCount":100},[],{"intervention":5508,"totalTrials":379,"cells":5509},"Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg",{"EARLY_PHASE1":5510,"PHASE1":5512,"PHASE2":5520,"PHASE3":5522,"PHASE4":5524,"NA":5526},{"trials":5511,"activeCount":100},[],{"trials":5513,"activeCount":100},[5514],{"nctId":5515,"briefTitle":5516,"status":108,"phases":5517,"primaryCompletion":1192,"completion":1192,"start":1209,"enrollment":721,"conditions":5518,"interventions":5519},"NCT00361790","Aripiprazole and Lexapro Drug Interaction Study",[89],[2076],[5508],{"trials":5521,"activeCount":100},[],{"trials":5523,"activeCount":100},[],{"trials":5525,"activeCount":100},[],{"trials":5527,"activeCount":100},[],{"intervention":5529,"totalTrials":379,"cells":5530},"SEP363856 150 mg",{"EARLY_PHASE1":5531,"PHASE1":5533,"PHASE2":5545,"PHASE3":5547,"PHASE4":5549,"NA":5551},{"trials":5532,"activeCount":100},[],{"trials":5534,"activeCount":100},[5535],{"nctId":5536,"briefTitle":5537,"status":108,"phases":5538,"primaryCompletion":5539,"completion":5539,"start":5540,"enrollment":5541,"conditions":5542,"interventions":5543},"NCT04369391","A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.",[89],"2020-11-10","2020-06-18",150,[15],[5529,5544],"moxifloxacin 400 mg",{"trials":5546,"activeCount":100},[],{"trials":5548,"activeCount":100},[],{"trials":5550,"activeCount":100},[],{"trials":5552,"activeCount":100},[],{"intervention":5544,"totalTrials":379,"cells":5554},{"EARLY_PHASE1":5555,"PHASE1":5557,"PHASE2":5563,"PHASE3":5565,"PHASE4":5567,"NA":5569},{"trials":5556,"activeCount":100},[],{"trials":5558,"activeCount":100},[5559],{"nctId":5536,"briefTitle":5537,"status":108,"phases":5560,"primaryCompletion":5539,"completion":5539,"start":5540,"enrollment":5541,"conditions":5561,"interventions":5562},[89],[15],[5529,5544],{"trials":5564,"activeCount":100},[],{"trials":5566,"activeCount":100},[],{"trials":5568,"activeCount":100},[],{"trials":5570,"activeCount":100},[],{"intervention":5572,"totalTrials":379,"cells":5573},"CTN SR1",{"EARLY_PHASE1":5574,"PHASE1":5576,"PHASE2":5588,"PHASE3":5590,"PHASE4":5592,"NA":5594},{"trials":5575,"activeCount":100},[],{"trials":5577,"activeCount":100},[5578],{"nctId":5579,"briefTitle":5580,"status":236,"phases":5581,"primaryCompletion":2290,"completion":2290,"start":5120,"enrollment":5470,"conditions":5582,"interventions":5584},"NCT02827513","A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects",[89],[5583],"Adult Attention-deficit Hyperactivity Disorder (ADHD)",[5572,5585,5586,5587],"CTN XR1","CTN XR2","CTN XR3",{"trials":5589,"activeCount":100},[],{"trials":5591,"activeCount":100},[],{"trials":5593,"activeCount":100},[],{"trials":5595,"activeCount":100},[],{"intervention":5585,"totalTrials":379,"cells":5597},{"EARLY_PHASE1":5598,"PHASE1":5600,"PHASE2":5606,"PHASE3":5608,"PHASE4":5610,"NA":5612},{"trials":5599,"activeCount":100},[],{"trials":5601,"activeCount":100},[5602],{"nctId":5579,"briefTitle":5580,"status":236,"phases":5603,"primaryCompletion":2290,"completion":2290,"start":5120,"enrollment":5470,"conditions":5604,"interventions":5605},[89],[5583],[5572,5585,5586,5587],{"trials":5607,"activeCount":100},[],{"trials":5609,"activeCount":100},[],{"trials":5611,"activeCount":100},[],{"trials":5613,"activeCount":100},[],{"intervention":5586,"totalTrials":379,"cells":5615},{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5624,"PHASE3":5626,"PHASE4":5628,"NA":5630},{"trials":5617,"activeCount":100},[],{"trials":5619,"activeCount":100},[5620],{"nctId":5579,"briefTitle":5580,"status":236,"phases":5621,"primaryCompletion":2290,"completion":2290,"start":5120,"enrollment":5470,"conditions":5622,"interventions":5623},[89],[5583],[5572,5585,5586,5587],{"trials":5625,"activeCount":100},[],{"trials":5627,"activeCount":100},[],{"trials":5629,"activeCount":100},[],{"trials":5631,"activeCount":100},[],{"intervention":5587,"totalTrials":379,"cells":5633},{"EARLY_PHASE1":5634,"PHASE1":5636,"PHASE2":5642,"PHASE3":5644,"PHASE4":5646,"NA":5648},{"trials":5635,"activeCount":100},[],{"trials":5637,"activeCount":100},[5638],{"nctId":5579,"briefTitle":5580,"status":236,"phases":5639,"primaryCompletion":2290,"completion":2290,"start":5120,"enrollment":5470,"conditions":5640,"interventions":5641},[89],[5583],[5572,5585,5586,5587],{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[],{"trials":5647,"activeCount":100},[],{"trials":5649,"activeCount":100},[],{"intervention":470,"totalTrials":379,"cells":5651},{"EARLY_PHASE1":5652,"PHASE1":5654,"PHASE2":5660,"PHASE3":5662,"PHASE4":5664,"NA":5666},{"trials":5653,"activeCount":100},[],{"trials":5655,"activeCount":100},[5656],{"nctId":463,"briefTitle":464,"status":108,"phases":5657,"primaryCompletion":466,"completion":466,"start":467,"enrollment":450,"conditions":5658,"interventions":5659},[89],[15],[56,470],{"trials":5661,"activeCount":100},[],{"trials":5663,"activeCount":100},[],{"trials":5665,"activeCount":100},[],{"trials":5667,"activeCount":100},[],{"intervention":5669,"totalTrials":379,"cells":5670},"OPB-51602",{"EARLY_PHASE1":5671,"PHASE1":5673,"PHASE2":5683,"PHASE3":5685,"PHASE4":5687,"NA":5689},{"trials":5672,"activeCount":100},[],{"trials":5674,"activeCount":100},[5675],{"nctId":5676,"briefTitle":5677,"status":108,"phases":5678,"primaryCompletion":2458,"completion":2458,"start":5679,"enrollment":2199,"conditions":5680,"interventions":5682},"NCT01423903","Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer",[89],"2010-02",[5681],"Advanced Cancer",[5669],{"trials":5684,"activeCount":100},[],{"trials":5686,"activeCount":100},[],{"trials":5688,"activeCount":100},[],{"trials":5690,"activeCount":100},[],{"intervention":5692,"totalTrials":379,"cells":5693},"VIS954",{"EARLY_PHASE1":5694,"PHASE1":5696,"PHASE2":5706,"PHASE3":5708,"PHASE4":5710,"NA":5712},{"trials":5695,"activeCount":100},[],{"trials":5697,"activeCount":100},[5698],{"nctId":5699,"briefTitle":5700,"status":108,"phases":5701,"primaryCompletion":5702,"completion":5702,"start":5703,"enrollment":5163,"conditions":5704,"interventions":5705},"NCT06212804","A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants",[89],"2024-07-19","2023-11-21",[32],[5692],{"trials":5707,"activeCount":100},[],{"trials":5709,"activeCount":100},[],{"trials":5711,"activeCount":100},[],{"trials":5713,"activeCount":100},[],{"intervention":3771,"totalTrials":379,"cells":5715},{"EARLY_PHASE1":5716,"PHASE1":5718,"PHASE2":5724,"PHASE3":5726,"PHASE4":5728,"NA":5730},{"trials":5717,"activeCount":100},[],{"trials":5719,"activeCount":100},[5720],{"nctId":3764,"briefTitle":3765,"status":108,"phases":5721,"primaryCompletion":1242,"completion":1242,"start":2971,"enrollment":3767,"conditions":5722,"interventions":5723},[89],[3769],[3757,3771],{"trials":5725,"activeCount":100},[],{"trials":5727,"activeCount":100},[],{"trials":5729,"activeCount":100},[],{"trials":5731,"activeCount":100},[],{"intervention":5733,"totalTrials":379,"cells":5734},"Brexpiprazole 1mg to 4mg",{"EARLY_PHASE1":5735,"PHASE1":5737,"PHASE2":5745,"PHASE3":5747,"PHASE4":5749,"NA":5751},{"trials":5736,"activeCount":100},[],{"trials":5738,"activeCount":100},[5739],{"nctId":5740,"briefTitle":5741,"status":108,"phases":5742,"primaryCompletion":1075,"completion":1259,"start":1095,"enrollment":24,"conditions":5743,"interventions":5744},"NCT01854944","PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia",[89],[15],[5733],{"trials":5746,"activeCount":100},[],{"trials":5748,"activeCount":100},[],{"trials":5750,"activeCount":100},[],{"trials":5752,"activeCount":100},[],{"intervention":5754,"totalTrials":146,"cells":5755},"Abilify MyCite®",{"EARLY_PHASE1":5756,"PHASE1":5758,"PHASE2":5760,"PHASE3":5762,"PHASE4":5774,"NA":5776},{"trials":5757,"activeCount":100},[],{"trials":5759,"activeCount":100},[],{"trials":5761,"activeCount":100},[],{"trials":5763,"activeCount":100},[5764],{"nctId":5765,"briefTitle":5766,"status":236,"phases":5767,"primaryCompletion":5768,"completion":5769,"start":5770,"enrollment":5771,"conditions":5772,"interventions":5773},"NCT03892889","A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®",[91],"2020-08-12","2020-09-29","2019-04-29",277,[15],[5754],{"trials":5775,"activeCount":100},[],{"trials":5777,"activeCount":100},[5778],{"nctId":5779,"briefTitle":5780,"status":108,"phases":5781,"primaryCompletion":1715,"completion":1715,"start":5782,"enrollment":5163,"conditions":5783,"interventions":5784},"NCT06372210","A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion",[93],"2023-06-26",[29,15,18,23],[5754]]